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8ABSTRACT
Introduction: A third of all patients with type 1 diabetes develop diabetic nephropathy
within 10 to 30 years, which leads to a decline in renal function and eventually to dialy-
sis or renal transplantation. This complication is associated with a 40-fold increase in the
incidence of cardiovascular disease and premature death. Substantial evidence exists for
genetic factors in the development and progression of the disease. The present study was
undertaken to investigate gene variations that may play a role in the pathogenesis of
diabetic nephropathy and its related traits.
Subjects and methods: The study uses a cross-sectional, case-control design compris-
ing 996 patients with type 1 diabetes. All patients were recruited from 20 referral centers
as a part of a nationwide multi-center study, the FinnDiane study. They were classified
into four groups according to their urinary albumin excretion rate. A number of previ-
ously characterized polymorphisms in the genes investigated were selected for each
study. The polymorphic region was amplified by polymerase chain reaction, and geno-
typing was performed by a solid-phase minisequencing method.
Results: The AA genotype of the functional –374 T/A polymorphism in the RAGE
gene located on chromosome 6p21.3 had a protective effect against proteinuria in pa-
tients with poor glycemic control, and against macrovascular disease. The Pro7 allele of
the Leu7Pro polymorphism of preproneuropeptide Y on chromosome 7p15.1 was asso-
ciated with poor glycemic control, proteinuria, higher triglycerides, and coronary heart
disease. The AA haplotype of the X-chromosomal AT2 gene was associated with a de-
cline in renal function and an increase in pulse pressure in males. Polymorphisms of the
nephrin and the DRD3 gene on chromosome 3q13.3 associated neither with diabetic
nephropathy, amount of proteinuria, serum lipids nor blood pressure.
Conclusion: This study suggests a gene–environment effect between the RAGE gene
and diabetic nephropathy. The AT2 gene may play a role in the male predominance of
diabetic nephropathy by influencing renal function and premature aging of the vascular
tree. The Pro7 allele of preproneuropeptide Y may be involved in the pathogenesis of
diabetic nephropathy through an impairment of glycemic control and lipids. No evidence
appeared for any involvement of the DRD3 or the nephrin gene in diabetic late compli-
cations.
91. INTRODUCTION
Diabetes mellitus was first described by
Aretaeus of Cappadocia 2000 years ago
(1). Diabetes is a Greek word meaning
“going through” used together with the
Latin mellitus originating from the Greek
meli, meaning “sweet” or “honey.” The
words thus describe remarkably well the
main symptoms of the disease, i.e., how
a major leakage of glucose into the urine
causes massive urine volumes, resulting
in excessive body fluid deprivation and
thirst. This much-feared disease, which
is caused by global destruction of the
insulin-producing islet cells in the pan-
creas, was untreatable and relentless,
resulting in ketoacidosis, cachexia, and
death within 1 to 2 years, until the dis-
covery of insulin by Banting and Best in
1922. The novel treatment with exoge-
nous insulin was doubtless one of the
major achievements in medicine during
the 20th century.
However, although exogenous insulin
saved the patients from early death, the
treatment could not entirely mimic the
physiological insulin production. Con-
sequently, the body was still exposed to
a more or less constant mild or moderate
hyperglycemia. Soon it was observed
that decades of supraphysiological blood
glucose levels in a subset of patients had
detrimental effects on the peripheral
nerves, heart, eyes, blood vessels, and
kidneys. An entirely new kidney disease
had entered the picture and was clinically
characterized by elevated blood pressure
(BP), proteinuria, and edema, eventually
leading to renal failure and uremia. Spe-
cific histological changes in the kidney
were soon discovered, and diabetic
glomerulosclerosis (diabetic nephropa-
thy) was first described by Kimmelstiel
and Wilson in 1936 (2). Patients with
diabetic nephropathy also showed a
dramatically increased mortality due to
cardiovascular disease, more diabetic eye
disease (retinopathy) causing blindness,
and more peripheral nerve destruction
(neuropathy) resulting in foot ulcers and
amputation.
Interestingly, only one-third of the
patients with type 1 diabetes will eventu-
ally develop clinically manifest neph-
ropathy (3,4). Although the presence of
hyperglycemia is crucial for disease
development, it cannot alone or even
together with a number of other envi-
ronmental factors explain this pattern.
Clinicians treating type 1 diabetic pa-
tients have always been perplexed by the
fact that some patients do not develop
any late diabetic complications despite
decades of even very poor glycemic
control, whereas others may develop
progressive diabetic nephropathy despite
fairly good glycemic control. Today,
evidence is convincing for genetic pre-
disposition to the disease, as shown by
large family studies (5) and as indicated
by a characteristic incidence peak of
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nephropathy after 15 to 20 years of dia-
betes (6). These studies, together with
several others, are clearly pointing to-
wards the presence of susceptibility
genes in the pathogenesis of diabetic
nephropathy.
This study was undertaken to explore
in patients with type 1 diabetes
biologically plausible candidate genes
coding for proteins that could interfere
with mechanisms leading to the initiation
or the progression of diabetic nephropa-
thy and other late complications. This
study utilizes a large, unique national
cohort of almost 1000 patients that is
part of the FinnDiane study.
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2. REVIEW OF THE LITERATURE
2.1. Classification of diabetes and its
late complications
Diabetes mellitus, a severe health prob-
lem with an incidence rapidly increasing
worldwide, comprises two distinct major
types. Approximately 10% of all diabetic
patients suffer from type 1 diabetes,
formerly called insulin-dependent dia-
betes mellitus (IDDM) or juvenile onset
diabetes. It is characterized by a progres-
sive autoimmune destruction of the insu-
lin-producing islets in the pancreas,
resulting in a complete loss of insulin
secretion. This is in total contrast with
the considerably more common type 2
diabetes, previously known as non-
insulin dependent diabetes mellitus
(NIDDM) or as maturity onset diabetes
mellitus. This disease is in the majority
of cases characterized by the metabolic
syndrome, which includes central obe-
sity, hypertension, dyslipidemia, im-
paired fibrinolysis, hyperuricemia, and
insulin resistance, and furthermore, by
increased gluconeogenesis and eventu-
ally insufficient insulin production. In
addition to these two major subtypes
there is a plethora of rarer forms of dia-
betes, which together account for less
than some 5 to 10% of all diabetes sub-
types (7,8).
Patients with both type 1 and type 2
diabetes show a substantially increased
risk for late complications. A common
denominator for all long-term microvas-
cular and macrovascular complications is
extensive vascular damage. In macrovas-
cular complications, accelerated athero-
sclerosis results in cardiovascular disease
(CVD) such as coronary heart disease
(CHD) and acute myocardial infarction
(AMI). In the lower extremities, mac-
rovascular disease manifests as periph-
eral vascular disease (PVD) resulting in
gangrene and amputation, whereas the
consequence of thrombosis in a brain
vessel is stroke. Microvascular compli-
cations comprise changes in the small
blood vessels of the eye that result in
diabetic retinopathy, in the peripheral
nerves, causing neuropathy, and finally
in the kidney, causing diabetic glomeru-
losclerosis or diabetic nephropathy.
2.2. Diabetic nephropathy in type 1
diabetes
2.2.1. Epidemiology and natural history
Only 30 to 45% of patients with type 1
diabetes will develop diabetic neph-
ropathy (3,4,6), although lower figures
also occur (9). Incidence of diabetic
nephropathy is at its peak after 10 to 15
years following the onset of diabetes (2-
3%) but falls to 0.5 to 1% after 20 years
12
of diabetes (10,11).
Figure 1 shows the natural history of
diabetic nephropathy. Its standard classi-
fication includes three stages according
to urinary albumin excretion rate
(UAER): 1) incipient nephropathy (mi-
croalbuminuria, UAER in an overnight
urinary collection 20-200 µg/min) lasting
5 to 15 years, 2) overt nephropathy
(proteinuria or macroalbuminuria,
UAER > 200 µg/min) lasting 5 to 10
years, and 3) end-stage renal disease
(ESRD) lasting 3 to 6 years without
dialysis or renal transplantation. Mogen-
sen a few years ago suggested a five-
stage classification by adding two stages
that precede microalbuminuria (12). The
first includes enlargement of the kidneys
(nephromegaly) as well as an increase in
glomerular filtration rate (hyperfiltra-
tion), and the second a transient period
of normal UAER. This latter stage can
be normalized by insulin treatment (13).
Since hyperfiltration predicts the devel-
opment of diabetic nephropathy, it is
considered necessary, but not sufficient,
for progression of the disease (14). Al-
though the first clinically applicable sign
of diabetic nephropathy is microalbu-
minuria, evidence exists that UAER
already in the upper normal range (10-20
µg/min) can predict progression to overt
nephropathy (15,16).
Figure 1. Natural history of diabetic nephropathy in type 1 diabetes. Adapted from
Jerums et al. (451). For abbreviations, see page 7.
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Microalbuminuria is a strong predic-
tor for overt diabetic nephropathy: Sev-
eral studies have shown that 75 to 100%
of microalbuminuric patients develop
diabetic nephropathy within 6 to 14
years (17-19). Although after 20 years of
diabetes duration its predictive value
decreases (11), risk is 20-fold higher
than in patients with normal UAER.
According to one recent study by Perkins
et al. (20), however, the predictive value
of microalbuminuria is significantly
lower, since they observed a 6-year cu-
mulative regression incidence of 58%
from microalbuminuria to normal
UAER. When microalbuminuria is
slowly progressing to proteinuria, a sig-
nificant increase in BP occurs (21,22),
although renal function at this stage is
usually normal. As the amount of prote-
inuria is increasing, concurrently glome-
rular filtration rate is declining at an
average 10 ml/min/year (22,23). Within
5 to 10 years, the patients enter ESRD,
characterized by total loss of renal func-
tion and clinically manifest uremia.
2.2.2. Comorbidity and mortality
Microalbuminuria also predicts prolif-
erative retinopathy (24), whereas overt
nephropathy predicts retinal disease
resulting in loss of vision (25). Patients
with diabetic nephropathy thus usually
have diabetic retinopathy. However,
although nearly all type 1 diabetic pa-
tients eventually develop retinopathy,
only a third will develop overt diabetic
nephropathy (26). Consequently, UAER
increases exponentially with elevated
BP, whereas UAER does not increase
with elevated BP in patients without
retinopathy.
If diabetic patients are treated with
insulin alone, their mortality rises to 50%
within 7 years after development of
proteinuria (3). The prognosis for a pa-
tient with type 1 diabetes is largely de-
pendent on the development of diabetic
nephropathy. There is already a 2-fold
increase in relative mortality for patients
without nephropathy, but a 40-fold in-
crease for those with proteinuria and at
maximum a 100-fold risk at age 35 due
to cardiovascular disease (27). These
figures are supported by more recent
figures for Finnish type 1 diabetic pa-
tients, showing a 10-fold increased risk
for patients with nephropathy in com-
parison to those without this complica-
tion (28).
2.2.3. Effect of treatment on progression
and prognosis
During the last 20 years the intensified
treatment of patients with ESRD, prote-
inuria, and microalbuminuria has led to a
substantial improvement in their long-
term prognosis.
Diabetic nephropathy does not occur
in the absence of hyperglycemia. The
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Diabetes Control and Complications
Trial (DCCT) showed that risk for dia-
betic nephropathy depends upon blood
glucose concentrations, i.e., the risk per
unit increase in glycosylated hemoglobin
A1c (HbA1c), is greater at high levels than
at low levels (29). Such a curvilinear
relationship between HbA1c level and
diabetic nephropathy has been chal-
lenged by Krolewski et al. (30), who
have suggested an HbA1c threshold value
of approximately 8%, below which the
risk for complications is substantially
reduced. The apparent benefit of intensi-
fied insulin treatment against diabetic
nephropathy is supported by the obser-
vation that any improvement in HbA1c
retards the progression of morphological
renal changes (31). It is noteworthy that
structural changes in diabetic nephropa-
thy in the kidney have even been com-
pletely reversed after 10 years of normo-
glycemia following pancreas transplan-
tation (32).
With insulin treatment alone, BP
increases by 6 mmHg per year in overt
nephropathy (12). Effective antihyper-
tensive treatment (AHT) delays the pro-
gression of diabetic nephropathy (33-35).
Angiotensin-converting enzyme (ACE)
inhibitors have a renal protective effect
(36-40) which appears in part to be inde-
pendent of its antihypertensive effect
(41). Although thus far no prospective
data exist for type 1 diabetes, it is likely
that the effect of angiotensin II type 1
receptor inhibitors is similar to that of
ACE inhibitors, as shown in large trials
in type 2 diabetic patients (42-44).
For type 2 diabetes, evidence indi-
cates that lipid-lowering therapy reduces
the level of microalbuminuria (45-47),
although these results are not consistent
(48). Although prospective data are
lacking, it is, however, also likely that
type 1 diabetic patients will benefit from
such therapy, since an association with
dyslipidemia already appears during the
microalbuminuric stage, an association
even more pronounced in overt neph-
ropathy (49).
Experimental animal models suggest
that low dietary protein intake retards the
progression of renal disease (50). Al-
though protein restriction is clearly bene-
ficial in non-diabetic renal disease (51),
and although it is frequently employed in
diabetic patients, evidence for an allevi-
ating effect in diabetic nephropathy is
still rather scarce (52-54). Similarly,
cessation of smoking is also likely to
slow the development and progression of
diabetic nephropathy despite a scarcity
of evidence for this (55-57).
The most radical improvement re-
garding the prognosis of the type 1 dia-
betic patient with nephropathy has been
renal replacement therapy. Conse-
quently, diabetes is today the most com-
mon diagnosis calling for dialysis or
renal transplantation, whereas patients
back in the 1970s were still considered
too ill for these treatments (58). Al-
though uremia rarely leads to death to-
15
day, life expectancy after initiation of
renal replacement therapy is scarcely
more than 5 to 7 years, because of the
high comorbidity with cardiovascular
disease (28).
In summary, active therapy both
before and after renal replacement ther-
apy has resulted in an improvement in
median survival time after onset of dia-
betic nephropathy from 7 years in the
1970s to 14 years now (59). In patients
with diabetic nephropathy, prognosis is,
however, still poor, and since the inci-
dence of type 1 diabetes is escalating, the
number of patients with type 1 diabetes
and nephropathy will increase. Focus
shall therefore be on preventative meas-
ures to avoid not only type 1 diabetes,
but also diabetic nephropathy. For its
prevention, novel strategies and treat-
ments are needed. These are dependent
on novel insights into the pathogenesis
of disease initiation and progression.
Only accurate understanding of the
mechanisms leading to diabetic neph-
ropathy can help us develop specific
treatment strategies and procedures.
2.2.4. Changes in renal structure
Kidney volume is already increased at
diagnosis of diabetes (60) and is most
likely caused by expansion of tubular
tissue (61). This probably explains why
in diabetes—in contrast to other chronic
renal diseases where the size is consid-
erably diminished—kidney size is, in
spite of ESRD, almost normal. The vol-
ume of the individual glomerulus is also
enlarged at diabetes diagnosis, and early
enlargement is probably due to enhanced
collagen production in the basement
membrane, whereas later enlargement is
probably caused by mesangial expansion
and continues to increase later in the
disease (62). Thickening of the glome-
rular basement membrane (GBM) is
perhaps the most omnipresent initial
lesion of diabetic nephropathy (63) along
with the mesangial expansion which
appears to occur later (64). The most
specific and pathognomonic lesions of
diabetic nephropathy, albeit not always
present, are the Kimmelstiel-Wilson
nodules (65). Hyaline deposits are also
specific for diabetic nephropathy: In the
afferent and efferent arterioles they can
be deposited between the endothelial cell
and the basement membrane as “fibrin
caps,” or finally as “capsular drops”
inside Bowman’s capsule (66).
During normal UAER or mild micro-
albuminuria (UAER 20-30 µg/min),
usually no consistent glomerular abnor-
malities appear. With UAER increase
comes an increase in thickness of the
GBM and in fractional volume of the
mesangium, simultaneously with a minor
reduction in creatinine clearance and a
rise in arterial BP (67,68). Although
UAER correlates with the severity of
glomerular lesions, considerable inter-
individual overlap occurs (68,69).
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2.3. Pathogenesis of diabetic
nephropathy
2.3.1. Environmental factors
Numerous environmental factors can
increase risk for diabetic nephropathy.
Some are poorly documented and ob-
servable only in association studies.
Table 1 summarizes environmental and
genetic risk factors for diabetic neph-
ropathy based on human studies.
2.3.1.1. Hyperglycemia
Supraphysiological blood glucose levels
over decades are necessary but not suffi-
cient to trigger the sequence of events
leading to diabetic nephropathy, since
only a subset of patients will eventually
develop this complication. Hyperglyce-
mia has been demonstrated to induce
vasodilatation and basement membrane
thickening, as well as apoptosis of en-
dothelial cells in vitro (70-72). High
glucose concentrations lead to an in-
creased synthesis of extra-cellular matrix
from mesangial cells, making them vul-
nerable to vasoconstrictors and resulting
in hyperfiltration (73,74). If normal
kidneys of rats and humans are trans-
planted into a hyperglycemic milieu,
they develop lesions typical of diabetic
nephropathy (75,76). On the other hand,
if normoglycemia can be permanently
restored, glomerular lesions typical for
diabetic nephropathy can disappear (32).
What are the mechanisms through
which hyperglycemia exerts its harmful
effect? During sustained hyperglycemia,
intermediate glycated Amadori-products
form. These are further transformed into
irreversible advanced glycation end-
products (AGEs). Amadori-albumin has
been proposed to cause microvascular
complications (77-79). Accumulation of
advanced glycation end-products (AGEs)
into tissue will interfere with long-lived
extracellular proteins, a process which
can then influence matrix production,
thickening of basement membrane, and
binding of heparan sulfate proteoglycans
(80). AGEs are increased during hyper-
glycemia and, as shown in animal studies
(81,82), can induce glomerulosclerosis
and albuminuria. The amount of AGEs
also correlates with diabetic nephropathy
and retinopathy (83), and AGEs can
predict changes in renal morphology of
type 1 diabetic patients (84). Interest-
ingly, if aminoguanidine, which is an
AGE inhibitor, is administered to ex-
perimental animals with diabetes, the
increase in mesangial volume is inhibited
and a decrease in UAER occurs
(82,85,86). Currently no data are avail-
able on aminoguanidine in humans, due
to its toxicity.
AGEs can interact with specific re-
ceptors, of which the best characterized
is the receptor for AGEs (RAGE). This
17
Table 1. Risk factors and markers for diabetic nephropathy ranked primarily according to
evidence of causality and secondarily to association studies in human type 1 diabetic
patients
Risk factor/marker Causality Association Available or potential treatment References
Microalbuminuria Strong Strong ACE inhibitor (17-19,285)
Glycemic control Strong Strong Improved glycemic control (29,346)
Upper  range normal UAER Evident Strong Blood pressure control (113,347)
Hyperfiltration Evident Evident Improved glycemic control (14,108,348)
Elevated blood pressure Uncertain Strong Antihypertensive treatment (21,22,113-115)
Increase in GBM thickness Uncertain Strong Improved glycemic control (68,69,349)
Mesangial expansion Uncertain Strong Improved glycemic control (68,69,349)
Dyslipidemia Uncertain Strong Statins, fibrates (49,149,154)
Familiar clustering Uncertain Strong NA (5,192,194,195)
Male sex Uncertain Evident NA (3,217)
Early onset of diabetes Uncertain Evident NA (6,112)
Smoking Uncertain Evident Cessation of smoking (350-352)
Insulin resistance Uncertain Evident PPAR-agonist (353-355)
Ethnicity Uncertain Evident NA (215,356)
Parental hypertension Uncertain Evident NA (117,118)
Parental CVD Uncertain Evident NA (205-207)
Low HSPG in GBM Uncertain Evident NA (176,357,358)
ACE I/D polymorphism Uncertain Evident NA (226,359,360)
High prorenin and renin Uncertain Evident NA (229,361)
High protein intake Uncertain Evident Protein restriction (51)
Na+/Li+ countertransport  Uncertain Uncertain NA (362)
Parental type 2 diabetes Uncertain Uncertain NA (202)
Endothelial dysfunction NK Evident Improved glycemic control (363)
AGEs NK Evident Aminoguanide (364)
High TGF levels NK Evident TGF inhibitors (365,366)
High PKC activity NK Evident PKC inhibitors (367)
Short stature NK Uncertain NA (163,167)
Low birth weight NK Uncertain NA (164)
No C-peptide production NK Uncertain C-peptide (368)
Na+/H+ exchanger activity NK Uncertain NA (369,370)
High iron deposits NK Uncertain Reduced iron intake (371)
Hyperandrogenicity NK Uncertain Testosterone antagonists (372,373)
Lack of physical exercise NK Uncertain Optimal amount of exercise (374)
High VEGF NK Uncertain NA (375)
High GH and IGF-1 levels NK Uncertain Somatostatin analogue (142)
Overactive polyol pathway NK Uncertain Aldose-reductase inhibitor (376)
Reduced number of glomeruli NK Uncertain NA (377)
Proliferative retinopathy Absent Strong Retinal laser treatment (29)
Neuropathy Absent Evident NA (29)
NA = not available, NK = not known. For other abbreviations, see page 7.
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receptor is expressed in renal interstitial
cells and vascular smooth muscle cells
(87); in experimental studies, AGE-
RAGE interaction has been shown to
induce oxidative stress (88). The co-
localization of RAGE in renal glomeruli
suggests that this AGE-RAGE interac-
tion may represent an important mecha-
nism in the pathogenesis of diabetic
complications (89). Interestingly, over-
expressed human RAGE in diabetic
transgenic mice induces glomerular
hypertrophy, increased albuminuria,
mesangial expansion, advanced glome-
rulosclerosis, and an increase in serum
creatinine none of which is evident in
mice lacking the RAGE transgene (90).
Moreover, a significant upregulation of
RAGE occurs in human vascular disease
(91). By blocking the AGE/RAGE
binding, the cellular changes associated
with formation of atherosclerosis in
animal models of diabetes are prevented
(92).
Hyperglycemia can also influence
other biochemical pathways. Aldose
reductase is the first and rate-limiting
enzyme of the polyol pathway in which
glucose is transformed into sorbitol. An
intracellular accumulation of sorbitol
occurs during hyperglycemia and, along
with disturbances in cellular osmoregu-
lation, results in tissue damage (93).
These metabolic abnormalities may be
involved in the pathogenesis of diabetic
nephropathy (94). Unfortunately, treat-
ment with tolrestat, an aldose reductase
inhibitor, has been disappointing in hu-
mans (95,96), although rats showed a
reduction in UAER (97,98).
Another common pathway suggested
to mediate the detrimental effects of
hyperglycemia is the activation of pro-
tein kinase C (PKC). Activation of PKC
stimulates extracellular matrix produc-
tion, expression of growth factors, and
contractility, permeability, and vascular
cell proliferation (99). Although no data
exist on inhibition in humans of the
PKC isoform, such inhibition in rats
prevents an increase in cytokine expres-
sion, reverses abnormal retinal and renal
hemodynamics, and also reduces UAER
(100).
It is also possible that glucose itself
has toxic effects on the cell. If cultured
human endothelial cells are chronically
exposed to high glucose concentrations,
they show abnormalities not due to an
altered polyol pathway (101). Chronic
hyperglycemia also results in increased
expression and synthesis of collagen,
fibronectin, and laminin (102), as well as
a decrease in heparan sulphate by me-
sangial cells (103). High glucose levels
in mesangial cells also induce the tran-
scription and secretion of transforming
growth factor beta (TGF) which stimu-
lates matrix synthesis and inhibits its
degradation (104).
19
2.3.1.2. Hemodynamic factors
During hyperglycemia an increase occurs
in cardiac output and peripheral vaso-
dilatation (105,106) which results in
disturbed autoregulation of the blood
flow in several organs and perhaps in
elevated BP in capillaries of several end-
organs (107). It has been suggested that
glomerular hypertension and hyperfiltra-
tion are key players in the pathogenesis
of diabetic nephropathy (108), since
elevated intraglomerular pressure can
alter the milieu within the glomerulus
and lead to an increase in protein filtra-
tion and protein accumulation in the
mesangium, as well as mesangial expan-
sion (108). Such an expansion may cause
stretching of mesangial cells, increased
extracellular matrix production, glome-
rular hypertrophy, and tubulointerstitial
inflammation (109).
Several animal models have shown
that BP control can prevent glomerulo-
sclerosis (110,111). In humans, elevated
arterial BP is an early phenomenon
(22,112), but whether it also precedes a
rise in UAER is debatable (113-116).
Evidence indeed exists for a parallel rise
in UAER and BP, as shown in a longitu-
dinal study using 24-hour ambulatory BP
monitoring in which baseline BP did not
differ between patients progressing to
microalbuminuria and non-progressors
(21). If this is true, the increase in blood
pressure could be considered a secondary
phenomenon and due to the renal dis-
ease. However, we have shown (117),
and also have confirmed earlier data
(118) that an elevated BP may even be a
primary phenomenon and may precede
the onset of renal disease, since BP is
significantly higher in parents of those
type 1 diabetic patients who develop
diabetic nephropathy than of those that
preserve a normal UAER. Such a view
supports the hypothesis that susceptibil-
ity to hypertension may also represent
susceptibility to diabetic nephropathy.
It is thus possible that common
pathogenetic mechanisms exist for the
elevated BP seen in non-diabetic subjects
and the initiation or progression of dia-
betic nephropathy in type 1 diabetic
patients. Data are convincing that
blocking the angiotensin-converting
enzyme (ACE) of the renin-angiotensin-
aldosterone system (RAAS) lowers BP
and postpones development of diabetic
nephropathy (41,119,120). A similar
blood-pressure lowering as well as reno-
protective effect is evident when the
angiotensin II type 1 receptor (AT1) is
blocked in type 2 diabetic patients with
diabetic nephropathy (42-44). It is of
note that in non-diabetic subjects the
angiotensin II type 2 receptor (AT2)
seems to oppose the deleterious effects
of the AT1 through vasodilatation and a
subsequent decrease in blood pressure
(121). AT2 stimulation also confers renal
protection in rats with progressive renal
injury (122), and is present in the rat
kidney in glomerular epithelial cells,
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cortical tubules, and interstitial cells
(123). Data regarding the impact of the
AT2 on diabetic nephropathy are scarce,
although alterations in the balance of
kidney AT1 and AT2 receptor expres-
sion have been reported to contribute to
the glomerular injury mediated by an-
giotensin II in progressive diabetic neph-
ropathy (124).
Another important renal hemody-
namic modulator is the dopamine sys-
tem. Dopamine is synthesized independ-
ently of nervous activity in the kidney
and it acts through at least five receptors,
all of which are expressed in the kidney
(125). An increase in renal dopamine
synthesis and stimulation of vascular
dopamine D1 receptors in diabetic rats
appears to prevent early glomerular
hyperfiltration (126). The synthesis and
secretion of renal dopamine have been
reported to be lower in diabetic neph-
ropathy in type 2 diabetic patients (127).
Interestingly, disruption of the dopamine
D3 receptor (DRD3) results in a renin-
dependent form of hypertension (128),
although this receptor has not yet been
studied in diabetic nephropathy.
Neuropeptide Y (NPY) is a vasomo-
toric polypeptide shown in experimental
studies to enhance basal renal blood flow
and to alter renal renin levels (129).
Stimulation of the NPY receptors has
resulted in an increase in sodium excre-
tion and a decrease in glomerular filtra-
tion rate, aldosterone concentration, and
plasma renin activity (130). NPY also
reduces the contractile response to
noradrenaline in rats, an effect enhanced
by hyperglycemia (131). In addition to
its role as a hemodynamic modulator,
NPY is an important regulator of energy
homeostasis (132) and is associated with
low-density lipoprotein (LDL) choles-
terol levels in non-diabetic subjects
(133). Data are rather scarce regarding
diabetic complications and NPY, al-
though both NPY and its Y2 receptor
have been associated with diabetic reti-
nopathy in type 1, as well as in type 2
diabetic patients (134,135).
2.3.1.3. Cytokines, growth factors, and
inflammation
Cytokines are peptides that are key play-
ers in tissue formation, cell differentia-
tion, and tissue repair. Several cytokines
are active in synthesis and degradation of
the GBM. Hyperglycemia induces an
increased expression of TGF in rats,
with subsequent renal hypertrophy and
increased formation of extracellular
matrix (136,137). During hyperglycemia
in diabetic nephropathy there also occurs
an increased synthesis and expression of
TGF, leading to cyclic stretching of
mesangial cells (138) and to progressive
matrix accumulation and tissue fibrosis
(139).
Among other growth factors, growth
hormone (GH) and insulin-like growth
factor (IGF-1) have been subject to much
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interest in regard to diabetic nephropa-
thy. GH and IGF-1 knock-out mice have
less glomerular hypertrophy and a lower
UAER than do GH/IGF-I intact rats
(140). When a GH antagonist gene is
transferred to mice, it causes also less
glomerular hypertrophy and a decreased
urinary protein content (141). Interest-
ingly, human type 1 diabetic patients
show an association between urinary
excretion of IGF-1 and renal volume as
well as between the excretion of these
two growth factors, GH and IGF-1, and
microalbuminuria (142).
Several other factors may prove of
interest in diabetic nephropathy, but thus
far only sparse information is available
regarding these substances in type 1
diabetes. Angiogenesis is induced by
vascular endothelial growth factor
(VEGF), a growth factor that also raises
vascular endothelial permeability in the
kidney (143). VEGF is also expressed by
the glomerular epithelial cell (143). The
cytokine interleukin-1 (IL-1) stimulates
mesangial cell proliferation (144), and in
diabetic rats, glomerular hyperperfusion
affects secretion of IL-1 beta. Interest-
ingly, the low-grade inflammatory mark-
ers IL-6 and hypersensitive C-reactive
protein (145), as well as mannose-
binding lectin (146,147), a component of
the complement system, have also been
associated with diabetic nephropathy in
type 1 diabetes. Angiotensin II, a strong
vasoconstrictor, induces glomeruloscle-
rosis independently of its hemodynamic
effect, and can also lead to diminished
matrix degradation (148).
2.3.1.4. Lipids
A typical feature of diabetic nephropathy
is hyperlipidemia (49). Whether hyper-
lipidemia causes glomerular injury re-
mains unknown, although lipid abnor-
malities are already present during mi-
croalbuminuria (49,149,150). Serum
triglyceride level is an independent risk
factor for diabetic nephropathy in type 1
(151) and type 2 diabetes (152). Lipid-
lowering treatment in almost totally
nephrectomized rats has been associated
with a small reduction in proteinuria and
glomerulosclerosis without any adverse
effects on renal function and plasma
lipid levels (153,154). In overt neph-
ropathy, hypercholesterolemia has been
associated with cardiovascular mortality
(155), and with a rapid decline in renal
function (155-157). Evidence also exists
that lovastatin treatment improves renal
function in rats (158), albeit no effect
was evident in patients with type 1 dia-
betes (159).
2.3.1.5. Short stature and low birth
weight
Short stature has been proposed as a
cardiovascular risk factor in non-diabetic
subjects (160-162). In diabetic patients,
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two Danish studies showed that males
with overt nephropathy were signifi-
cantly shorter than males with microal-
buminuria or normal UAER (163,164).
The mechanism is unknown, although an
adverse intrauterine environment (165),
hyperglycemia, parental social class
(166,167), and genetic factors (166) have
been suggested.
The Barker hypothesis suggests an
association between low birth weight and
cardiovascular mortality (168), hyperten-
sion (169,170), BP (171,172), and other
features of the insulin resistance syn-
drome (173). The notion that this is
caused by environmental factors is sup-
ported by the observation that the
smaller twin of a genetically identical
monozygotic twin pair has the higher BP
later in life. Intrauterine environmental
factors may thus affect BP differently
despite a common genetic background
(174). Our own studies have shown that
birth weight is inversely correlated with
systolic BP and pulse pressure (PP),
although its relation to diabetic neph-
ropathy remains to be established (175).
2.3.1.6. Glomerular capillary wall
Endothelial dysfunction reflects a gener-
alized vascular process affecting the
glomeruli and large vessels. According
to the Steno hypothesis, the barrier be-
tween capillary and urinary space loses
its negative charge selectivity due to the
loss of heparan sulfate proteoglycan
(HSPG) content (176). This results in an
increase in leakage of albumin through
the capillary wall and may thus be one
initiating mechanism behind microalbu-
minuria. A more recent study has con-
firmed in type 1 diabetes the reduction in
HSPG in the GBM, although that study
provided no evidence for its involvement
with early microalbuminuria (177).
The glomerular podocyte layer has
drawn much recent attention with the
discovery—in the Finnish type of con-
genital nephrosis—that the nephrin pro-
tein is absent, with a subsequent lack of
slit diaphragm and foot processes plus
massive proteinuria already in uteri
(178). Adult type 1 diabetic patients
show down-regulation of nephrin mRNA
and a loss of the electron dense structure
of the slit diaphragm, thereby suggesting
a novel mechanism for diabetic neph-
ropathy (179). Interestingly, a reduction
in expression of the nephrin gene and
protein can be attenuated by an AT1
blocker (180,181) or an ACE inhibitor
(182,183). Nephrin has also been con-
nected in the diabetic mouse with early
changes in diabetic nephropathy (184),
and downregulation of the nephrin pro-
tein may be due to glycated albumin and
angiotensin II (185). Recent studies
suggest, however, that other proteins
integrated with nephrin, such as the
CD2-associated protein and podocin,
may together contribute to the patho-
genesis of proteinuria (186). Leakage of
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nephrin into the urine has also recently
been suggested to be an early marker of
diabetic nephropathy (187).
2.3.2. Genetic factors
Today, substantial evidence exists for the
role of genetic factors in the pathogene-
sis of diabetic nephropathy, although the
inheritance pattern is not as yet known.
A plausible genetic model may be one or
two major genes with a dominant or
recessive effect interacting with envi-
ronmental factors, or a few genes with a
moderate effect in a similar interaction
(188). Diabetic nephropathy thus may
represent a typical complex disease such
as type 1 diabetes plus asthma. The pro-
portion of the genetic involvement in a
complex disease is often expressed as
sibling recurrence risk, or lambda S (S),
which is the risk of a sibling’s develop-
ing the disease which the other sibling
already has. As can be calculated from
the study of Quinn et al. (5), S in dia-
betic nephropathy is approximately 2 to
2.5, lower than that calculated for type 1
diabetes (S = 15) (189) or for asthma
(S = 3-5) (190).
2.3.2.1. Incidence studies
In diabetic nephropathy, incidence rate
peaks about 15 years after diabetes diag-
nosis, after which it declines substan-
tially (3,4,6,191), in sharp contrast to
diabetic retinopathy, where no such peak
is apparent and incidence rate is linear.
This observation can be interpreted to
imply that some genes either expose the
subject to or protect the subject from
diabetic nephropathy during a certain
time-span (188). If, after 25 years, a
patient with diabetes still has a normal
UAER, the lifetime risk of developing
overt nephropathy and ESRD is small.
2.3.2.2. Familial clustering and herita-
bility
Familial clustering of diabetic neph-
ropathy has provided strong evidence for
genetic involvement. The original obser-
vation by Seaquist et al. (192) showed
elevated UAER in 83% of diabetic sib-
lings of patients with diabetic nephropa-
thy, whereas among siblings with a nor-
mal UAER, only 17% had nephropathy.
Although these original figures were
criticized as genetically implausible
(193), three later studies have confirmed
this finding, despite the fact that their
degree of familial clustering seems to be
considerably lower (5,194,195). Al-
though such figures may be due to shar-
ing of the same environment, simulation
studies have shown that environmental
factors cannot entirely account for the
familial aggregation of such a trait (196).
The genetic model of diabetic neph-
ropathy is still unclear, partly due to the
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fact that no available data exist from
twin studies, in contrast to such condi-
tions as type 1 diabetes, in which the
concordance rate has been 27% in
monozygotic and 4% in dizygotic twins
(197). However, in diabetic nephropathy
of type 2 diabetic patients, a single major
locus or a dominant model with addi-
tional multifactorial effects is proposed,
based on recent segregation analyses
(198,199). It is noteworthy, in contrast,
that one large study reported familial
clustering for retinopathy but not for
nephropathy in type 1 diabetes, although
this lack of correlation may have been
due to the short duration of diabetes in
the diabetic offspring (200). On the other
hand, there appears to be strong concor-
dance between severity and patterns of
glomerular lesions in type 1 diabetic
siblings despite their simultaneous lack
of concordance for glycemia, which
supports a theory of genetic factors’
affecting diabetic nephropathy (201).
There also appears to be familial
clustering of certain risk factors in dia-
betic nephropathy. We and others have
discovered more hypertension (117,118),
type 2 diabetes (202), and insulin resis-
tance (203) in parents of patients with
type 1 diabetes and overt nephropathy
than in those with normal UAER. Simi-
larly, parents of patients with diabetic
nephropathy also have higher mortality
and more CVD, although these findings
are not consistent (202,204-207).
Nondiabetic first-degree relatives of type
2 diabetic patients with diabetic neph-
ropathy seem to show have an elevated
UAER in comparison to those with nor-
mal UAER (208) (209-211), although
this may not be the case in type 1 diabe-
tes (212).
2.3.2.3. Ethnic variation
Substantial differences in prevalence of
diabetic nephropathy have emerged
between various ethnic groups. African-
Americans have a 5-fold increased risk
for developing ESRD compared to Cau-
casian type 2 diabetic patients, which
cannot be explained by differences in
glycemic control or in diabetes duration
(213). This increased risk in African-
Americans may, however, be a marker of
an inherited susceptibility to develop-
ment of renal disease, rather than to
development of diabetic nephropathy.
Similarly, incidence of diabetic ESRD in
Native Americans is 7-fold higher than
in the Caucasian population (214).
Among Jews with type 1 diabetes, the
non-Ashkenazis are at higher risk for
nephropathy than are other Jewish
groups (215).
2.3.2.4. The role of gender
Due to the paucity of large prospective
studies, the role of gender is not entirely
clear. Because of the excess cardiovas-
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cular mortality in both diabetic and non-
diabetic males (216), results of preva-
lence studies may be biased, undermin-
ing any potential difference between
males and females. Evidence does exist
that in males both the prevalence of
diabetic nephropathy is higher (3) and
the progression of ESRD is faster
(3,217). This male preponderance is
further supported by an 18-year follow-
up study from Denmark in which male
gender was an independent predictor for
microalbuminuria (218).
2.4. Genetic approaches to complex
traits and diabetic nephropathy
A complex genetic trait implies that the
phenotype is not the result of classic
Mendelian recessive or dominant in-
heritance caused by a variation in a sin-
gle gene at a single locus. Since the
cumulative incidence of diabetic neph-
ropathy is approximately 30%, it is likely
that several genes each play only a mod-
est role in the disease process. The two
major approaches in the search for sus-
ceptibility genes for complex traits are
linkage analysis and association studies,
the latter often referred to as candidate
gene studies.
2.4.1. Linkage analysis
Traditional linkage analysis requires that
certain estimates must be provided for all
variables for the traits studied, including
mode of inheritance, penetrance, pheno-
copies, and gene frequencies (219). This
approach usually requires a rather high
number of sibling pairs or larger pedi-
grees. Regarding sibling pairs, an allele-
sharing method can be used requiring no
disease model variables, since it relies on
affected relatives, each sharing a differ-
ent proportion of alleles than would
occur randomly.
In a genome-wide scan, markers
randomly spread over the entire genome
cover all chromosomes. If one marker is
inherited from each parent more often
than predicted, linkage has occurred, and
consequently, this region may harbor a
susceptibility gene. This method requires
no previous knowledge of the putative
gene. In diabetic nephropathy in type 1
diabetes, currently no genome-wide
scans are published, and the number of
linkage studies is also small. One such
linkage study concentrated on markers at
three loci in the RAAS (220), and found
significant linkage to chromosome 3q in
the region harboring the angiotensin II
type 1 receptor gene (AT1). However,
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although the gene was not entirely cov-
ered in that study due to very extensive
intronic regions, no variants of the AT1
gene showed any association with dia-
betic nephropathy. What cannot be ruled
out is whether a nearby unknown gene
could have been responsible for the link-
age observed. The locus on 3q23-24 is
now replicated in a very recent Russian
study (221). Regarding diabetic neph-
ropathy in type 2 diabetic patients, thus
far only one genome-wide scan has ap-
peared, and that study found linkage on
chromosomes 7, 3, 9, and 20 (222).
2.4.2. Association studies
This method requires identifying genetic
variations or polymorphisms in a candi-
date gene that may alter the coding se-
quence or transcription activity and may
thus alter the function or expression of
proteins involved in the disease process.
The design most frequently used is a
case-control study. The frequency of
gene variation in subjects with a disease
(cases) is compared to the frequency of
those without disease (controls). This
approach suffers substantially, however,
from both false positive (type I error)
and false negative results (type II errors),
highlighted by its rather low reproduci-
bility. This may be due to a spurious
association with a number of causes such
as genetic heterogeneity or the presence
of phenocopies. Appropriate and care-
fully characterized cases and controls are
thus needed.
In order to overcome these problems,
alternative designs have been developed.
In nuclear family or trio designs, the
transmission disequilibrium test (TDT)
requires no control group, since the
genotypes of the patient’s parents are
known (223). Such a family-based study
scrutinizes how the putative disease
allele is transmitted to the patients from
their heterozygous parents. If it is trans-
mitted in significantly more often than in
half of the cases, the disease allele is
associated with the trait.
2.5. Candidate gene studies of diabetic
nephropathy in patients with type 1
diabetes
As mentioned, there are no published
genome-wide scans in diabetic neph-
ropathy in type 1 diabetic patients, due to
the difficulty in enrolling a sufficient
number of sibling pairs concordant or
discordant for diabetic nephropathy,
partly since there is a long time-span
between onset of diabetes and ascertain-
ment of nephropathy status. In addition,
patients with type 1 diabetes and ESRD
have high mortality rates, and of course
incur rather high expense for a genome-
wide scan. Studies on the genetics of
diabetic nephropathy in type 1 diabetes
have therefore been almost entirely asso-
ciation studies. Due to the several factors
27
suggested to be involved in the patho-
genesis, numerous candidate genes have
already been studied in patients with
diabetic nephropathy. These have fre-
quently included genes that have previ-
ously been studied in hypertension, type
2 diabetes, and cardiovascular disease
(224). None of the associations of gene
variants with diabetic nephropathy found
have been convincingly and undisput-
edly replicated in other populations or in
prospective studies.
2.5.1. The renin-angiotensin-aldosterone
system
The genes of the RAAS have drawn
special attention in diabetic nephropathy,
since it is well known that ACE inhibi-
tors effectively reduce proteinuria be-
yond the reduction in BP levels (41).
Consequently, the A C E inser-
tion/deletion (I/D) polymorphism is the
polymorphism most studied. A total of
27 publications during the last 10 years
deal with the ACE I/D polymorphism;
these show rather high variability. Two
meta-analyses have indicated a weak
association for the D-allele as a risk
marker for diabetic nephropathy in
which the odds ratio (95% confidential
interval) was 1.12 (0.95-1.32) (225,226).
Table 2 summarizes published candidate
gene studies on the ACE I/D as well as
on other genes of the RAAS in diabetic
nephropathy in type 1 diabetes.
Another important gene studied in
the RAAS is the angiotensinogen gene.
A positive association appeared for the
M235T polymorphism in a TDT study in
male subjects (227). Otherwise, results
also conflict in regard to this polymor-
phism (Table 2).
Table 2. Candidate genes in the RAAS studied in type 1 diabetic patients with neph-
ropathy
Gene Polymorphism Positive association
Reference
No association
Reference
ACE I/D (225,226,306,359,360,378-385) (296,386-398)
ACE PstI (297)
Angiotensinogen (AGT) M235T (227,398,399) (359,387,391,395,397,400,401)
AT1 A1166C (220,397,398,402-405)
AT1 T573C (406)
Bradykinin 1 receptor G-699C (228)
Renin BglI (229)
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The angiotensin II type 1 receptor gene
(AT1) has been the focus of several
studies, partly because of the study by
Moczulski et al. (220), showing a strong
linkage in the region containing this
gene. However, association studies have
mainly been negative for the AT1 gene.
Other genes of the RAAS studied com-
prise the bradykinin-1 receptor, not asso-
ciated with nephropathy in a Caucasian
cohort of both type 1 and type 2 diabetic
patients (228). Interestingly, in a Danish
cohort, a positive association appeared
between a polymorphism in the renin
gene and diabetic nephropathy (229).
Unfortunately, this finding has not been
replicated in other populations. Despite
interest in the angiotensin II type 2
receptor (AT2) as one of the key players
in the RAAS, the corresponding gene
(AT2) has as yet not been studied in
diabetic nephropathy.
2.5.2. Genes related to blood pressure
Since, in patients with diabetic neph-
ropathy, elevated BP is a characteristic
feature, genes involved in BP regulation
have drawn much attention, as summa-
rized in Table 3. One interesting ques-
tion is whether the pronatriodilatin gene,
coding the atrial natriuretic factor (ANP),
is involved in diabetic nephropathy.
Table 3. Candidate genes related to blood pressure studied in type 1 diabetic patients
with nephropathy
Gene Polymorphism Positive association
Reference
No association
Reference
Alpha adducin Gly460Trp (236)
ATP1 A1 Bgl II (407)
Beta3 adrenergic receptor Trp64Arg (408)
Epithelial sodium channel BetaArg564X (409)
G-protein beta 3 C825T (410) (411,412)
Nitric oxide 3 (eNOS) 4a/b (233) (234,235)
Nitric oxide 2A CCTTT-repeat (413)
Nitric oxide 2A promoter (235)
Pronatriodilatin (ANP) Scal (230)
Pronatriodilatin (ANP) T2238C (231)
Pronatriodilatin (ANP) HpaII (intron 2) (232)
SA hypertension-associated homologue Pst1 (414)
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Thus far, results have been rather con-
flicting (230-232). Given the substan-
tially large variation between these
studies, it could be argued that this dis-
crepancy is due to ethnic differences. A
positive association appeared between
the endothelial nitric oxide gene (eNOS)
and advanced diabetic nephropathy in an
American cohort examined by both case-
control and family design (233-235).
Although the alpha-adducin gene has
been associated with essential hyperten-
sion, in a type 1 diabetic cohort from
Ireland and Northern Ireland no associa-
tion existed between this gene and dia-
betic nephropathy or hypertension (236).
Although the dopamine system
regulates BP (125), and although all
dopamine receptor genes (DRD1-DRD5)
have been characterized, no studies thus
far have explored diabetic complications.
One potential gene in this family is the
DRD3, since disruption of this gene in
mice results in a renin-dependent form of
hypertension (128).
2.5.3. Genes related to cardiovascular
disease
Due to the high prevalence in diabetic
nephropathy of early atherosclerosis and
cardiovascular complications, genes
associated with CVD have frequently
been studied as candidate genes for
nephropathy, as shown in Table 4. The
C677T polymorphism of the methyle-
netetrahydrofolate reductase (MTHR)
gene is associated with plasma homo-
cystein levels, which may contribute to
cardiovascular disease (237). This poly-
morphism has been studied by
Table 4. Candidate genes related to cardiovascular disease studied in type 1 diabetic
patients with nephropathy
Gene Polymorphism Positive association
Reference
No association
Reference
Apolipoprotein E e2,e3,e4 (243,244) (245,246)
Beta3 integrin PlA1/PlA2 (415)
Beta-fibrinogen G455A (416)
Methylenetetrahydrofolate reductase C677T (238,242) (239-241)
Plasminogen activator inhibitor-1 4G/5G (390,417)
Paraoxonase 1 (PON1) Several (418)
Paraoxonase 2 (PON2) Several (419)
Werner syndrome helicase C/R (390)
von Willebrand factor T789A, A138T (420)
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several groups in regards to diabetic
nephropathy, but the results are again
conflicting (238-242). Prospective stud-
ies are needed to further elucidate the
role of this gene. A quite similar con-
stellation exists for the e2, e3, and e4
alleles of the apolipoprotein E gene, with
two positive (243,244) and two negative
studies (245,246).
Interestingly, a functional Leu7Pro
polymorphism of the preproneuropeptide
Y has been associated with carotid athe-
rosclerosis, serum LDL cholesterol lev-
els, triglycerides, and BP in Finnish
non-diabetic subjects (133,247,248).
The Leu7Pro has also been associated
with both retinopathy and carotid athero-
sclerosis in Finnish type 2 diabetic pa-
tients (135,249). Its role in late compli-
cations in type 1 diabetic patients has,
however, not yet been elucidated.
2.5.4. Genes related to diabetes, immu-
nology, and glucose metabolism
The first candidate gene study involving
patients with diabetic nephropathy was
published in 1991. Raffel et al. (250)
Table 5. Candidate genes related to diabetes, immunology, and glucose metabolism
studied in type 1 diabetic patients with nephropathy
Gene Polymorphism Positive association
Reference
No association
Reference
Genes related to diabetes and immunology
Complement C4 C4AQ0 (421)
ENPP1/PC-1 K121Q (380)
Human leucocyte antigen Several (251)
Hepatocyte nuclear factor 1 b E260D,Q378Q (422)
Insulin Ins+/- (251)
Insulin 5’end (250)
Genes involved in glucose metabolism
AGE-receptor 1 Several (255)
AGE-receptor 2 Several (255)
AGE-receptor 3 Several (255)
AGE-receptor (RAGE) Several (255)
Aldose reductase (CA)n (220,252,423,424) (254,425,426)
GLUT1 XbaI (427,428) (429)
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found a positive association between a
polymorphism in the 5’end of the insulin
gene, a finding not yet consistently repli-
cated (251).
A few other studies dealing with
genes related to diabetes and glucose
metabolism have been performed, as
shown in Table 5. Regarding the aldose
reductase gene (AL2), a group from the
UK found a strong association in Cauca-
sian patients between a (CA)n repeat and
diabetic nephropathy (2 = 18.6, P <
0.00001) (252). Interestingly, this posi-
tive association was later repeated in an
American cohort (253), but not in an-
other cohort of Caucasian patients from
the UK (254). Poirot et al. (255) detected
a positive association between longer
duration of nephropathy-free diabetes
and the C-1152A polymorphism of the
RAGE gene promoter, an association
later complicated by discovery of a
pseudogene adjacent to the RAGE pro-
moter (256). No replication study deal-
ing with this interesting gene has ap-
peared.
2.5.5. Genes related to glomerular
structure
Although the basic structure of the
glomerulus and its proteins are well
characterized, the genes regulating these
proteins and glomerular function are
rather poorly known. Only a few candi-
date genes have been studied regarding
structural proteins, as seen in Table 6.
Table 6. Candidate genes related to glomerular structure studied in type 1 diabetic
patients with nephropathy
Gene Polymorphism Positive association
Reference
No association
Reference
Caldesmon -579A>G (260)
Collagen IVA1 HindIII (430)
Decorin 179/183/185 (258)
Heparan sulphate proteoglycan BamHI (257)
A study in a combined Danish-British
cohort with respective 260 + 397 patients
showed a weak positive association
between BamHI polymorphism of the
heparan sulphate core protein (HSPG)
gene and UAER (257). This finding has
not been confirmed, although it supports
the Steno hypothesis that a defect in the
GBM leads to loss of charge selectivity
and subsequent proteinuria (176). An
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allelic variant of another basement mem-
brane gene, decorin, has been associated
in a longitudinal study with a 6.5 year-
follow-up with a slower progression of
nephropathy (258).
Dysfunction of the glomerular actin
cytoskeleton, a component of the glome-
rular podocyte layer, occurs in diabetic
nephropathy (259). Interestingly, a posi-
tive association was recently found in
two distinct Irish cohorts between dia-
betic nephropathy and caldesmon, one of
the genes coding the actin cytoskeleton,
(260). Another important protein, a ma-
jor component of the glomerular slit
membrane called nephrin, was discov-
ered several years ago (178). Several
mutations in the nephrin gene (NPHS1)
lead to a complete loss of nephrin from
the slit diaphragm and cause the Finnish
type of congenital nephrosis character-
ized by massive proteinuria and early
death (261). It can, however, be hypothe-
sized that some mutations lead to a mi-
nor defect in the protein, instead of a
total loss of the protein. In a diabetic
milieu, such a defect probably could
cause a milder degree of proteinuria.
2.5.6. Other genes
A few other genes mostly dealing with
cytokines and growth factor have been
scrutinized in diabetic nephropathy, as
seen in Table 7.
Table 7. Genes related to growth factors and enzymes studied in type 1 diabetic patients
with nephropathy
Gene Polymorphism Positive association
Reference
No association
Reference
Interleukin-1A C/T -889 (262,263)
Interleukin-1B ex5 T/C (262) (263)
Interleukin-1R1 ex1B T/C (262,263)
Interleukin-1RN intr2  86 bp rep. (262,263)
N-acetyltransferase fast/slow (431)
Nuclear factor kappa  A1-A18 (432)
Transforming growth factor 1 Several (264)
Transforming growth factor 1 Thr263Ile (265)
VEGF D/I -2549 (266)
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Two groups studying the interleukin
system on chromosome 7q35 showed
that the IL-1 cluster is not a key player in
the development of diabetic nephropathy
(262,263), although a peak containing
this IL-1 locus appeared in a genome-
wide scan in type 2 diabetic patients with
nephropathy (222). Several polymor-
phisms of the TGF gene have been
characterized, and two candidate gene
studies published regarding this gene and
diabetic nephropathy. However, as so
often occurs, the results are rather con-
flicting (264,265). A recent study found
a positive association between variants in
the VEGF gene and diabetic nephropathy
in type 1 diabetic patients from the UK
(266). Interestingly, this association was
further strengthened when analyzed
together with polymorphisms in the
aldose reductase gene, suggesting a
gene-gene interaction.
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3. AIMS OF THE PRESENT STUDY
Diabetic nephropathy is associated with massively increased risk for cardiovascular
disease and early mortality. Although only a subset of the patients with type 1 diabetes
will develop this devastating complication and evidence is convincing for a genetic im-
pact in its pathogenesis, the predisposing genes have been hitherto unknown. The studies
in this thesis were performed to answer the following questions concerning type 1 dia-
betic patients:
1. Are three common polymorphisms in the receptor for the advanced glycation end-
products gene (RAGE) involved in pathogenesis of diabetic nephropathy and other late
complications? (I)
2. Are three exonic polymorphisms in the nephrin gene (NPHS1) associated with prote-
inuria or renal function? (II)
3. Is the Leu7Pro polymorphism of the preproneuropeptide Y (NPY) associated with
glycemic control, lipid profile, BP levels or macrovascular complications? (III)
4. Is any polymorphism or haplotype studied in the dopamine D3 receptor gene (DRD3)
associated with diabetic nephropathy, renal function or BP levels? (IV)
5. Can any of the two polymorphisms or haplotypes studied in the X-chromosomal an-
giotensin II type 2 receptor gene (AT2) explain the male predominance in diabetic neph-
ropathy, or is the gene associated with renal function or BP levels? (V)
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4. SUBJECTS AND STUDY DESIGN
4.1. Study population
This study was part of the ongoing Fin-
nish Diabetic Nephropathy (FinnDiane)
Study; a comprehensive multicenter,
nationwide project launched in Novem-
ber 1997, with the aim of phenotyping
20 to 25% of all adult patients with type
1 diabetes in Finland, and to study dia-
betic late complications. All patients
with type 1 diabetes available in the
FinnDiane database in August 1999 were
classified  according  to  their  UAER, as
shown in Figure 2. At that time there
were 1006 classifiable patients with an
ascertained renal status in the FinnDiane
database from 20 secondary or tertiary
referral centers. All patients were re-
quired to be C-peptide-negative (< 0.3
nmol/l), and to have permanent insulin
treatment initiated within one year after
the diabetes diagnosis and before age 40.
Patients with evidence of non-diabetic
kidney disease were excluded. Eventu-
ally, 996 patients participated.
Figure 2. Flow-chart depicting recruitment procedure for study subjects.
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Their clinical characteristics are shown
in Table 8. Subjects from Helsinki Uni-
versity Central Hospital, Department of
Medicine, Division of Nephrology
(n=217), were recruited between
November, 1994 and June, 1999, and all
others (n=779) between March, 1998 and
June, 1999. Clinical descriptions of the
subjects in each referral center are in
Table 9.
Table 9. Clinical characteristics by referral center
Hospital n Males NO MI PR ES CVD Age DUR HbA1c GFR
All 996 54 32 17 33 19 11 41 ± 10 28 ± 8 8.5 ± 1 77 ± 33
Helsinki University CH 217 59 23 8 35 35 15 43 ± 9 30 ± 8 8.6 ± 1 65 ± 39
Satakunta CH 109 48 35 15 37 14 10 40 ± 11 27 ± 8 8.3 ± 1 73 ± 30
Seinäjoki CH 93 56 52 18 25 5 8 42 ± 10 28 ± 9 8.6 ± 1 87 ± 27
Savonlinna CH 72 54 50 17 25 8 8 42 ± 9 27 ± 8 8.0 ± 1 85 ± 29
Päijat-Häme CH 56 54 29 13 41 18 7 38 ± 10 26 ± 8 7.9 ± 1 79 ± 32
Central Ostrobothnian CH 54 54 52 31 9 7 9 40 ± 11 28 ± 8 8.1 ± 1 90 ± 22
CH of Lansi-Pohja 54 50 46 24 26 4 9 40 ± 10 26 ± 7 9.4 ± 2 85 ± 28
CH of Kanta-Hame 50 54 8 24 50 18 14 44 ± 9 29 ± 8 8.6 ± 1 66 ± 31
Kainuu CH 47 62 38 26 30 6 9 38 ± 9 25 ± 9 8.9 ± 2 89 ± 28
North Karelian H 43 44 58 12 21 9 0 40 ± 11 27 ± 8 7.9 ± 1 84 ± 26
Vasa CH 41 66 0 24 59 17 12 39 ± 10 27 ± 8 8.9 ± 1 72 ± 35
Turku University CH 33 52 0 0 0 100 21 45 ± 8 33 ± 9 8.6 ± 2 53 ± 29
South Karelia CH 32 41 31 16 47 8 13 38 ± 11 27 ± 9 8.1 ± 1 80 ± 30
Tampere University H 25 40 0 12 68 20 20 38 ± 8 28 ± 7 9.3 ± 1 60 ± 20
CH of Kymenlaakso 22 82 36 41 23 0 0 32 ± 8 22 ± 8 8.4 ± 1 104 ± 22
Central Finland CH 19 32 53 11 21 16 5 34 ± 10 24 ± 9 8.5 ± 1 88 ± 32
Mikkeli CH 18 56 0 33 61 6 11 38 ± 11 26 ± 9 9.0 ± 2 79 ± 33
Lapland CH 6 67 67 33 0 0 0 44 ± 6 31 ± 6 8.5 ± 1 94 ± 20
City of Turku HC 4 0 50 0 50 0 25 51 ± 7 35 ± 9 8.4 ± 1 56 ± 23
CH of Åland Islands 1 100 0 0 1 0 0 58 ± 0 46 ± 0 7.5 ± 1 37 ± 0
Male column and classes by UAER are in %, all other columns are values ± SD.
NO=normoalbuminuria, MI=microalbuminuria, PR=proteinuria, ES=end-stage renal
disease, DUR=duration of diabetes, GFR=glomerular filtration rate according to Cock-
croft-Gault formula, CH=central hospital, H=hospital, HC=health center.
4.2. Ethical aspects and informed
consent
The study protocol followed the ethical
principles expressed in the Declaration
of Helsinki. The Ethics Committee of
the Helsinki University Central Hospital
endorsed the protocol in 1997. In addi-
tion, the local ethics committees of all
participating hospital districts approved
the study. All subjects received written
information about the study prior to their
participation and gave their written con-
sent.
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4.3. Study design
All studies had a cross-sectional, case-
control study design. All the 996 subjects
took part in each study, and were divided
into four groups according to their
UAER. Genotype and allele frequencies
as well as haplotypes were compared
between patients in the four groups, or
between clinical variables biologically
appropriate for each gene. Additionally,
males and females were analyzed sepa-
rately in all studies. The Hardy-
Weinberg distribution was assessed for
each polymorphism and each patient
group.
4.3.1. Study I
In Study I, two common functional po-
lymorphisms in the promoter region
(–429 T/C and –374 T/A) and one in
exon 3 (G82S) of the RAGE gene on
chromosome 6p21.3 were genotyped.
The genotypes, allele frequencies, and
genotype combinations were analyzed
with respect to nephropathy, renal func-
tion, retinopathy, CVD, AHT, serum
lipids, diabetes duration, and glycemic
control. Separate analyses were per-
formed for the genotypes based on gly-
cemic control between patients with
normal UAER and those with proteinu-
ria. Any variables showing a positive
association were tested separately in
multiple regression analyses.
4.3.2. Study II
The focus in Study II was on three po-
lymorphisms in the nephrin gene
(NPHS1) on chromosome 19q13.1. Thus,
the E117K in exon3, R408Q in exon 10,
and N1077S in exon 27 were genotyped
for an association study in which the
genotypes, allele frequencies, and geno-
type combinations were compared along
with proteinuria and duration, to the
diagnosis of microalbuminuria, proteinu-
ria, or ESRD. Furthermore, the study
tested whether any differences emerged
in serum creatinine values, UAER levels,
or serum creatinine clearance between
the genotypes. Any possible association
between any genotype combination and
these variables was also assessed. In
addition, three suggested polymorphisms
(T295I, E447K, and R1140C in exons 8,
11, and 27, respectively) were genotyped
and tested in 82 patients in order to elu-
cidate whether they were true polymor-
phisms or were rare variants present only
in the relatives of patients with congeni-
tal nephrosis.
4.3.3. Study III
Study III concerned genotyping of the
functional Leu7Pro polymorphism of
preproneuropeptide Y. Analy-
ses—performed in all patients and sepa-
rately in a constellation, excluding those
with ESRD—determined whether geno-
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types or allele frequencies were associ-
ated with serum lipids, glycemic control,
arterial BP, AHT or CVD. All variables
with a positive association were entered
into a multiple regression analysis to test
whether they were independently associ-
ated.
4.3.4. Study IV
Study IV focused on the DRD3 gene on
chromosome 3q13.3. In this gene, two
polymorphisms located in exon 1
(Ser9Gly and Ala17Ala) and one in the
promoter region (–707 G/C) were geno-
typed. Analyses showed whether any
association existed between the geno-
types, allele frequencies or haplotypes
and BP levels, AHT, CVD and variables
involved with renal function.
4.3.5. Study V
Study V involved genotyping of one
functional polymorphism in intron 1
(G1675A), and one in intron 2 (A1818T)
of the AT2 gene. Because of its X-
chromosomal location, all analyses were
performed separately between males and
females. The genotypes, allele frequen-
cies, and haplotypes were compared with
BP levels, glycemic control, renal func-
tion, and prevalence of CVD, AHT,
diabetic nephropathy, and retinopathy.
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5. METHODS
5.1. Phenotype assessments
Attending physicians and nurses caring
for the patients collected clinical data
from all subjects recruited for the
FinnDiane study. All physicians were
diabetologists or nephrologists and the
nurses trained in diabetology or nephrol-
ogy. All data—collected during a regular
visit to the hospital—included a thor-
ough medical history, BP, height,
weight, and waist and hip measurement,
as well as one timed 24-hour urine col-
lection and drawing of blood samples. In
addition, all patients completed a ques-
tionnaire concerning their medical his-
tory.
5.1.1. Medical history
The extensive information collected from
these subjects concerned diabetes and
late complications, hypertension, renal
function, regular medication, previous
laboratory values, chronic diseases other
than diabetes, and socio-economic fac-
tors, as well as the medical history of
parents and siblings. Questionnaires
were designed particularly for the
FinnDiane study.
A patient was classified as having
type 1 diabetes if the diagnosis was made
prior to the 40th birthday and if insulin
treatment was initiated within one year,
and if any oral antidiabetic medication
ceased within one year of diagnosis.
Based on a complete list of regular
medications, patients with treatment
potentially affecting kidney function
were excluded. Smoking was defined as
present smoking of at least one daily
cigarette, cigar, or pipe during the year
prior to participation. The patient was
defined as an ex-smoker if more than one
year had passed since cessation of
smoking.
All local laboratory values available
from the last 10-year period and relevant
to diabetes and late diabetic complica-
tions went to the FinnDiane coordinating
center in Helsinki. Variables requested
were: HbA1c, serum total cholesterol,
serum triglycerides, serum high-density
lipoprotein (HDL) cholesterol, and se-
rum creatinine. LDL cholesterol was
calculated by the Friedewald formula
(267). Similarly, all available local uri-
nary albumin measurements provided
were used for the classification of neph-
ropathy.
5.1.2. Classification of nephropathy
The physician in charge of each patient
reported whether the patient had previ-
ously been diagnosed with microalbu-
minuria, overt proteinuria, or ESRD.
However, the final classification into 1)
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Normal UAER (normoalbuminuria), 2)
Microalbuminuria, 3) Proteinuria (overt
nephropathy), or 4) ESRD was per-
formed centrally and assessed according
to the UAER in at least two of three past
consecutive overnight or 24-hour urine
collections. All patients with a normal
UAER (< 20 g/min or < 30 mg/24
hours, n = 317) were required to have
had a diabetes duration more than 15
years. A total of 164 patients had micro-
albuminuria (AER 20-200 g/min or 30-
300 mg/24 hours), 325 had proteinuria
(UAER > 200 g/min or > 300 mg/24
hours), and 184 ESRD. All ESRD pa-
tients were further classified as on dialy-
sis (n=44) or with a kidney transplant
(n=140). If abnormal UAER was diag-
nosed during pregnancy only, these val-
ues were not taken into consideration in
the classification procedure.
5.1.3. Retinopathy
Retinopathy was recorded either as any
retinopathy or proliferative retinopathy.
The patient was considered to have pro-
liferative retinopathy if he or she had
undergone retinal photocoagulation.
5.1.4. Blood pressure and hypertension
Systolic (SBP) and diastolic (DBP) clini-
cally tested office blood pressure,
registered as Korotkoff I and V sounds,
was measured in each center with a cali-
brated mercury sphygmomanometer.
Two measurements were performed,
each after at least 10 minutes of rest. The
mean value served for statistical analy-
sis. Pulse pressure was calculated as SBP
minus DPB. Hypertension was defined
as regular use of at least one antihyper-
tensive agent such as an angiotensin-
converting enzyme (ACE) inhibitor,
angiotensin II type 1 receptor inhibitor,
diuretic, calcium-channel inhibitor, or
beta-blocker.
5.1.5. Cardiovascular disease
Information about CVD came from
medical records and included verified
CHD, AMI, or stroke. The patients were
considered to have CHD if they had
suffered an AMI reported by their physi-
cian, undergone a coronary by-pass or
percutaneous transluminal coronary
angioplasty (PTCA), or if they were
permanently using short- or long-acting
nitroglycerin or both. The patients quali-
fied for AMI if they had signs of a previ-
ous myocardial infarction in the electro-
cardiogram assessed by the physician.
All classified as having PVD were re-
quired either to have had bypass surgery
performed on either leg or to have had at
least one toe or leg amputated.
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5.1.6. Anthropometric measurements and
insulin sensitivity
Body weight was registered to the clos-
est 0.1 kg and height to the closest 1 cm,
in light clothing without shoes. Body
mass index (BMI) was calculated as
weight/height2 (kg/m2). Waist circumfer-
ence was measured midway between the
iliac crest at the midaxillary line and the
lowest rib; hip circumference was at the
widest part of the gluteal region. Waist-
to-hip ratio (WHR) was calculated as
waist/hip (cm/cm) and served as an indi-
cator of central obesity. Estimated glu-
cose disposal rate (eGDR), a surrogate
for insulin sensitivity, was calculated
according to the formula (mg x kg-1 x
min-1), as suggested by Williams et al.
(268).
5.2. Sample collection and laboratory
assays
Of 85 ml of blood drawn by venopunc-
ture, 60 ml was drawn into six EDTA
tubes for genetic analyses, as described
in section 5.3; 20 ml was drawn into two
serum tubes and 5 ml into a tube con-
taining aprotinin. Patients were also
asked for a 24-hour urine sample. Blood
and urine samples were immediately
deep frozen and stored at -20° C. Urinary
albumin concentration was measured
centrally with RIA (Pharmacia, Uppsala,
Sweden). Serum and urine creatinine
concentration levels for calculation of
creatinine clearance were measured by
the modified Jaffé reaction with a Hi-
tachi 911 E Automatic Analyser (Boe-
hringer Mannheim, Mannheim, Ger-
many) and serum C-peptide concentra-
tions with a Human C-peptide RIA kit
(Linco Research Inc, St Charles, MO,
USA), at the central laboratory. Glome-
rular filtration rate (GFR) was calculated
by the Cockcroft-Gault formula (269).
HbA1c, serum cholesterol, and serum
triglycerides were measured by routine
methods at the local laboratory of each
referral center. Normal range for HbA1c
was 4.0 to 6.0% in 75% of the local
laboratories, and in all centers the upper
normal value was below 7.0%. For
triglycerides, the normal range was 0.4
to 1.7 mmol/l in 55% of the centers, and
in all centers the upper normal range was
below 2.0 mmol/l in 90% and below 3.0
mmol/l. For total serum cholesterol, the
normal range was < 5.0 mmol/l in 40%
of the centers, and the upper normal
range was below 7.0 mmol/l in 95%. For
serum HDL cholesterol these were, re-
spectively, > 1.0 mmol/l in 40% and >
0.8 mmol/l in 100% of the centers. All
local laboratories had participated in a
national quality assessment program.
Plasma NPY was measured centrally
with a commercial radioimmunoassay
(RIA) kit EURIA-NPY (Euro-
Diagnostica Inc., Malmö, Sweden).
From the 24-hour urine collection, uri-
nary sodium (Na+) and potassium (K+)
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were measured centrally by a standard-
ized ion selective electrode technique
(normal ranges, 130-240 mmol/l and 60-
90 mmol/l, respectively).
 5.3. Genotyping
Deoxyribonucleic acid (DNA) was ex-
tracted from whole blood according to
standard protocols with slight modifica-
tions (270). In all studies, genotyping
was performed by the minisequencing
method, in which one of the primers in
each polymerase chain reaction (PCR)
was biotinylated (271,272), except for
the Leu7Pro polymorphism in Study III
where a BsiEI restriction enzyme was
used (133). The PCR primers were or-
dered form the Genethon Database (273)
except for Study III (133). In all studies,
the PCR protocol was run in 96-well
microtitration plates by use of a MJ
Research programmable thermal cycler
(MJ Research, Watertown, MA, USA).
Study I. For amplification of the
region containing the –429 T/C and –374
T/A polymorphisms in the RAGE gene,
primers were as described (274), but
with an added biotinylated F5’ end.
Minisequencing of the –429 T/C and
–374 T/A was determined with
reverse minisequencing primers
5’-AGGAGAGAAACCTGTTTGGA-3’ and
5’-CTGTTGTCTGCAAGGGTGCA-3’,
respectively. The G82S primers have
been described (275), with the
forward minisequencing primer
5’-TGGCTCGTGTCCTTCCCAACG-3’.
Study II. The PCR primers for all
polymorphisms in the nephrin gene were
identical to those used by Lenkkeri et al.
(261). For the E117K polymor-
phism located in exon 3 was used a
reverse minisequencing primer:
5’-CACGAGCTCGGGCCCCATCT-3’, but
for the R408Q and N1077S polymor-
phisms located in exon 10 and 24, re-
spectively, a forward minisequencing
primer 5’-CTGACATTCCTGGCGCGG-3’
and 5’-GGGCTTCTGCTCCTCTCC-3’.
Genotyping of the E117K polymorphism
failed in 35 patients (3% of the total
study population) because of spurious
results in the minisequencing reaction,
whereas for the R408Q and N1077S
polymorphisms, PCR failure occurred
only in one and in five patients. Fur-
thermore, three suggested polymor-
phisms: the T295I in exon 8, E447K in
exon 11, and R1140C in exon 27, were
genotyped according to previously de-
signed PCR primers (276,277) using
forward minisequencing primers of
5’-AGCGTGGGGCACAGAGCACA-3’,
5’-CCGCCCAGAAACTGTGGATT-3’, and
5’-CAGAGGCAGAGCCGTATTAC-3’,
respectively.
Study III. The Prepro-NPY Leu7Pro
genotypes were determined according to
a previously described method (133).
Due to failure of the PCR reaction, one
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patient remained ungenotyped.
Study IV. The Ser9Gly and the
Ala17Ala sites located on exon 1 of the
DRD3 gene were included in the same
PCR reaction using the forward primer
5’-TTTCTGTCTCCTCACAGGAA-3’
a n d r e v e r s e p r i m e r
5’-CAGCAGGCCATTGCCGAA-3’. Large
sections with no previously known po-
lymorphisms in the DRD3 coding region,
promoter, and 3' end were systematically
sequenced by another group at the same
institution (unpublished data) using stan-
dard sequencing procedures in 12
healthy control patients. Only one previ-
ously unknown A to G substitution in
codon 17 (Ala17Ala) at base position
278 bp (GENEBANK accession
U25441) was discovered. The forward
minisequencing primers in the Ser9Gly
and Ala17Ala variants were
5’-CATCTCTGAGTCAGCTGAGT-3’ and
5’-CTGAACTACACCTGTGGGGC-3’. The
PCR primers in the –707 G/C
p o l y m o r p h i s m h a v e b e e n
described (278), in which the
5’-TGGGAAGAATCTGGAGCTCA-3’
minisequencing primer is used for
genotyping of this polymorphism.
Study V. The PCR primers of the
G1675A and the A1818T polymor-
phisms of the AT2 gene have been de-
scribed elsewhere (279). For these poly-
morphisms, the minisequencing primers
were 5’-CTGTATTTTGCAAAACTCCT-3’
and 5’-TTATGTTAATTTGTTAGGTC-3’.
Genotyping of the G1675A polymor-
phism failed in two patients due to PCR
failure.
5.4. Statistical methods
5.4.1. General
Descriptive data, unless otherwise stated,
are expressed as standard error of mean
(± SEM), standard deviation (± SD), or
median value (range). Categorical vari-
ables were compared by the chi-squared
test. Normally distributed continuous
variables were subjected to Student’s t-
test, while non-normally distributed
variables were logarithmically trans-
formed or assessed by the Mann-
Whitney U-test. Differences between
multiple groups were tested with analysis
of variance (ANOVA), but with the
Kruskal-Wallis test if the variables were
not normally distributed. To evaluate any
independent association between vari-
ables for any dependent categorical vari-
able, a backward stepwise multiple lo-
gistic regression model was used with a
means substitution of absent data. Be-
tween variables for any dependent con-
tinuous variable, a backward stepwise
multiple linear regression model was
used. All statistical analyses were also
performed separately for each gender.
Analyses were carried out with the
STATISTICA 4.1 statistical package
(Tulsa, OK, USA).
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5.4.2. Linkage disequilibrium and
haplotypes
In Studies I and II, the linkage dise-
quilibrium (LD) analyses were per-
formed with the LinkDos and Genepop
packages (version 1.2) (280) and the
distribution of genotype combinations by
the MENDEL program (281). In Study
IV, LD analyses between the markers
were performed by use of the 2 by 2
program, version 1.50 (282), and
haplotypes were determined using the
PHASE version 2.0.1 (283). In Study V,
LD was analyzed with the Linkage Dise-
quilibrium Analyzer 1.0 (284), and
haplotypes were determined by PHASE
version 2.0.2 (283). The haplotypes in
Studies IV and V were imported into a
STATISTICA 4.1 file and compared
with all variables of interest. Males and
females were always analyzed separately
in Study V.
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6.  RESULTS
6.1. RAGE polymorphisms in relation
to proteinuria and cardiovascular
disease (I)
The RAGE –374 T/A and G82S poly-
morphisms were in Hardy-Weinberg
equilibrium for all four groups divided
according to their UAER. However, the
–429 T/C polymorphism deviated sig-
nificantly from equilibrium (c2 = 20.8, p
< 0.0001). The frequencies of the homo-
zygous mutant genotype for the –429
T/C, –374 T/A, and G82S polymor-
phisms were 2, 13, and 1%, respectively.
No differences in genotypes or allele
frequencies appeared between the four
groups. AA genotype frequency of the
–374 T/A polymorphism was 15% in
patients with normal UAER compared to
12% in those with proteinuria (p = NS).
In patients with poor glycemic control
(HbA1c > 9.5), however, the AA geno-
type of the –374 T/A polymorphism was
significantly more common in subjects
with a normal UAER (30%, n = 27) than
in those with proteinuria (10%, n = 91)
(Figure 3).
In a similar analysis, HbA1c levels
were unaffected by genotype frequencies
of the –429 T/C and G82S polymor-
phisms (data not shown).
Figure 3. Patients (%) with the homozy-
gous minor genotype (AA) of the RAGE
–374 T/A polymorphism. All patients
with normal UAER and proteinuria ana-
lyzed with their HbA1c by interval. *P =
0.01.
Table 10. Genotype distribution and
macrovascular complications by –374
T/A polymorphism in all patients
Variable AA TT+TA P
CVD+ 6 (6) 100 (94)
CVD- 124 (14) 757 (86) 0.01
CHD+ 5 (6) 80 (94)
CHD- 120 (14) 752 (86) <0.05
AMI+ 1 (2) 52 (98)
AMI- 128 (14) 804 (86) 0.01
PVD+ 1 (2) 40 (98)
PVD - 129 (14) 815 (86) <0.05
All data given as n (%). P-value by two-
tailed Fisher’s exact test. For abbre-
viations, see page 7.
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Among the 106 patients with mani-
fest CVD, it was less common in those
with the AA genotype than with the TT
and TA genotypes of the –374 T/A
polymorphism. In addition, patients with
the AA genotype had less CHD, fewer
AMIs, and less PVD (Table 10).
Furthermore, the AA genotype of the
–374 T/A polymorphism was independ-
ently associated with CVD (p = 0.009, R
= 0.40, beta = -0.983) in the multiple
logistic backward regression analysis.
The model also included gender, age,
HbA1c, serum triglycerides, waist-to-hip
ratio, current smoking, AHT, and paren-
tal CVD. In addition to the RAGE –374
T/A polymorphism, AHT (p < 0.001,
beta = 1.819), HbA1c (p = 0.008, beta =
0.137), and age (p < 0.001, beta = 0.093)
were associated independently with
CVD.
6.2. Nephrin gene polymorphisms and
diabetic nephropathy (II)
The three polymorphisms of the nephrin
gene were in Hardy-Weinberg equilib-
rium for all other groups except for the
N1077S polymorphism in subjects with
microalbuminuria, where a slight devia-
tion was observed (2 = 4.34, p < 0.05).
The minor allele frequencies in the
E117K, R408Q, and N1077S polymor-
phisms, located in exons 3, 10, and 24,
were 34, 8, and 12% in the entire cohort.
No differences in genotype- or in allele
frequencies were evident between any of
the four groups when they all were ana-
lyzed together, or when the genotype- or
the allele frequencies were analyzed
separately for each group (Table 11).
Power calculations indicated that the
cohorts were sufficiently large to yield
Table 11. Distribution of genotypes and rare allele frequencies of nephrin polymor-
phisms
Polymorphism NORMO MICRO PROT ESRD P
E117K NS
EE 146 (46) 73 (44) 140 (44) 65 (40)
EK 132 (41) 75 (46) 134 (43) 68 (42)
KK 40 (13) 17 (10) 41 (13) 30 (18)
K 0.33 0.33 0.34 0.39 NS
R408Q NS
RR 273 (85) 140 (84) 267 (82) 156 (85)
RQ 45 (14) 26 (16) 58 (18) 24 (13)
QQ 3 (1) 0 (0) 0 (0) 3 (2)
Q 0.08 0.08 0.09 0.08 NS
N1077S NS
NN 242 (76) 128 (77) 253 (78) 145 (78)
NS 74 (23) 32 (19) 67 (21) 38 (21)
SS 3 (1) 6 (4) 3 (1) 1 (1)
S 0.13 0.13 0.11 0.11 NS
Genotypes as n (%). For abbreviations, see page 7.
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80% power to detect a 9% deviation in
rare genotype frequency at p < 0.05, and
had 99.5% power to detect a 14% devia-
tion in genotype difference. All three
polymorphisms were in LD with each
other (p < 0.0001). With respect to the
T295I, E447K, and R1140C polymor-
phisms in exon 8, 11, and 27, none
among the 82 first patients genotyped
possessed the minor allele, and thus no
further genotyping was performed.
Patients with the wild genotype and
patients with one or two rare alleles of
each polymorphism showed no differ-
ence in length of time from onset of
diabetes to diagnosis of nephropathy or
onset of ESRD, or in any of the meas-
ured renal variables (Table 12). No
genotype combination was associated
with ESRD, proteinuria, or AHT, but the
genotypes E117E, R408Q, and N1077N
were more prevalent in ESRD individu-
als with CHD cases than in the other
genotypes (p = 0.04). This positive asso-
ciation disappeared, however, after the
correction for multiple testing.
Table 12. Clinical by nephrin genotypes
Polymorphism Wild genotype Minor genotypes P-value
GFR (ml min-1 1.73 m-2)a
E117K 83 ± 28 81 ± 30 NS
R408Q 83 ± 29 79 ± 30 NS
N1077S 82 ± 30 83 ± 30 NS
Urinary sodium excretion (mmol/day)a
E117K 154 ± 65 153 ± 70 NSb
R408Q 156 ± 69 153 ± 62 NSb
N1077S 156 ± 69 155 ± 65 NSb
Urinary potassium excretion (mmol/day)a
E117K 85 ± 33 88 ± 33 NSb
R408Q 87 ± 69 87 ± 62 NSb
N1077S 88 ± 33 85 ± 33 NSb
UAER (mg/24 h)c
E117K 665 ± 1188 832 ± 1258 NS
R408Q 725 ± 1159 916 ± 1530 NS
N1077S 882 ± 1225 655 ± 1221 NS
Time from onset of DM to nephropathy (years)
E117K 19 ± 7 19 ± 8 NS
R408Q 19 ± 7 19 ± 8 NS
N1077S 19 ± 7 20 ± 7 NS
Time from onset of DM to ESRD (years)
E117K 26 ± 8 26 ± 7 NS
R408Q 26 ± 8 27 ± 7 NS
N1077S 26 ± 7 28 ± 9 NS
Data are ± SD. DM=type 1 diabetes. aPatients with ESRD excluded. bP = NS when only
patients without permanent medication except for insulin (n=182) were included. cOnly
patients with microalbuminuria and proteinuria included.
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6.3. NPY Leu7Pro polymorphism and
late complications (III)
Genotype frequencies for all four groups
were in Hardy-Weinberg equilibrium.
The frequency of the Pro7 substitution
was 11% for patients with normal
UAER, 10% for those with microalbu-
minuria, 16% for those with proteinuria,
and 13% for patients with ESRD (2 =
5.48, df = 3, p = 0.14). The Pro7 substi-
tution was more common in patients
with overt nephropathy than in patients
with normal UAER (2 = 4.00, df = 1, p
< 0.05).
HbA1c, triglycerides, BMI, and CVD
prevalence were significantly higher in
subjects with the Pro7 substitution than
in those with the Leu7/Leu genotype
(Table 13). Since the majority of pa-
tients with ESRD had received a renal
transplant and thus had a normal UAER
at the time of investigation, and since
this group also has a potential survival
bias, data presented do not include pa-
tients with ESRD. In addition, total cho-
lesterol was higher and eGDR lower in
patients with the Pro7 substitution.
Therefore, it was not unexpected that
insulin dose was also higher in females
with the Pro7 substitution. No differ-
ences between genotypes appeared in
SBP or DBP, PP, or prevalence of AHT,
AMI, or stroke.
Plasma NPY was 111.5 ± 3.0 nmol/l
in those with the wild type genotype and
110.3 ± 4.4 nmol/l in those with the Pro7
substitution (p = NS). No differences
were detectable when males and females
were analyzed separately, nor were there
any differences when subjects with pro-
teinuria and normal UAER were ana-
lyzed separately nor when the patients
were divided into quintiles according to
their plasma NPY. The plasma NPY was
96.7 ± 2.7 nmol/l in those with normal
UAER in comparison to 121.3 ± 3.5
nmol/l in those with proteinuria (p <
0.001). Positive correlations appeared
between plasma NPY and HbA1c (r =
0.24, p < 0.001), total cholesterol (r =
0.40, p < 0.001), LDL cholesterol (r =
0.23, p < 0.001), and serum creatinine (r
= 0.51, p < 0.001). The Leu7Pro geno-
type was also independently associated
with proteinuria, CHD and HbA1c in
multiple regression analyses (Table 14).
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Table 14. Multiple backward stepwise
regression analyses
A. Linear regression with HbA1c as de-
pendent variable. Patients with ESRD
excluded. Complete data available from
679 patients. Other variables included in
the first model: sex, serum creatinine,
triglycerides, SBP, and lipid-lowering
medication. Adjusted R2 = 0.14.
Variable Coefficient SEM P
Age -0.023 0.005 <0.001
Triglycerides 1.205 0.260 <0.001
LDL cholesterol 0.290 0.060 <0.001
WHR 1.492 0.617 0.016
NPY Leu7Pro 0.555 0.156 <0.001
B. Logistic regression with proteinuria
vs. normal UAER as dependent variable.
Complete data available from 679
patients. Other variables included in first
model: sex, BMI, and current smoking.
R2 = 0.69.
Variable Coefficient SEM P
Diabetes duration -0.031 0.015 0.036
HbA1c 0.207 0.090 0.022
Triglycerides 2.942 0.613 <0.001
LDL cholesterol 0.543 0.168 0.001
AHT 5.287 0.598 <0.001
NPY Leu7Pro 1.250 0.457 0.006
C. Logistic regression with CHD as
dependent variable in all patients.
Complete data available from 957
patients. Other variables included in first
model: sex, LDL cholesterol, WHR, and
current smoking. R2 = 0.14.
Variable Coefficient SEM P
Age 0.092 0.010 <0.001
HbA1c 0.160 0.055 <0.005
AHT 1.645 0.365 <0.001
NPY Leu7Pro 0.634 0.229 0.006
For abbreviation, see page 7.
6.4. DRD3 gene polymorphisms, blood
pressure, and diabetic nephropathy
(IV)
All DRD3 polymorphisms studied were
in Hardy-Weinberg equilibrium for all
four patient groups. Frequencies for the
minor alleles were 18, 30, and 10% for
the –707 G/C, Ser9Gly, and Ala17Ala
genotypes, respectively. Power calcula-
tions showed that cohorts were suffi-
ciently large to yield 80% power to de-
tect an 11% deviation in rare genotype
frequency at p < 0.05, and had 99.5%
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power with one marker to detect a 13%
deviation between the four groups as
shown by power calculations. The –707
G/C and Ala17Ala were in tight LD with
the Ser9Gly (D = 0.13, D’ = 1.00 and
D = 0.07, D’ = 0.98, respectively, p <
0.0001).
No differences in genotypes or in
allele frequencies were evident among
the four groups (Table 15).
Table 15. Distribution by genotypes, minor allele frequencies, and haplotypes of the
DRD3 polymorphisms according to UAER
NORMO MICRO PROT ESRD P
Polymorphism
-707 G/C:   GG 210 (65) 113 (68) 233 (72) 113 (61)
GC 102 (32) 46 (28) 82 (25) 62 (34)
CC 9 (3) 7 (4) 10 (3) 9 (5) NS
C 0.19 0.18 0.16 0.22 NS
Ser9Gly:    AA 153 (48) 81 (49) 174 (54) 80 (43)
AG 140 (44) 70 (42) 123 (38) 80 (44)
GG 28 (9) 15 (9) 28 (9) 24 (13) NS
G 0.31 0.30 0.28 0.35 NS
Ala17Ala:    AA 263 (82) 134 (81) 263 (81) 145 (79)
AG 53 (17) 29 (17) 59 (18) 38 (21)
GG 5 (2) 3 (2) 3 (1) 1 (1) NS
G 0.10 0.11 0.10 0.11 NS
Haplotypes
G-Ser-A 446 (70) 232 (70.) 470 (72) 238 (65) NS
C-Gly-A 120 (19) 60 (18) 102 (16) 80 (22) NS
G-Gly-G 63 (10) 35 (11) 64 (10) 38 (10) NS
G-Gly-A 13 (2) 5 (2) 13 (2) 10 (3) NS
G-Ser-G 0 0 1 (0) 2 (1) NS
Genotype and haplotype data are n (%). For abbreviations, see page 7. Haplotype order:
-707 G/C, Ser9Gly and Ala17Ala (A/G).
We observed five haplotype combina-
tions but no differences between the
groups (Table 15). In addition to the
variables in Table 16, no differences
appeared in the prevalence of AHT,
CVD, or CHD in any of the polymor-
phisms when comparing patients with
the wild genotype to patients with one or
two minor alleles. Neither were there any
associations between the genotypes and
endpoints like initiation of AHT, onset of
diabetic nephropathy, or ESRD.
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Table 16. Clinical variables by DRD3 genotype
Polymorphism Wild genotype Minor genotypes P
SBP (mmHg)
-707 G/C 140 ± 20 141 ± 19 NS
Ser9Gly 140 ± 20 141 ± 20 NS
Ala17Ala 141 ± 17 141 ± 19 NS
DBP (mmHg)
-707 G/C 82 ± 10 82 ± 10 NS
Ser9Gly 82 ± 10 82 ± 10 NS
Ala17Ala 82 ± 10 82 ± 11 NS
PP (mmHg)
-707 G/C 59 ± 18 59 ± 17 NS
Ser9Gly 58 ± 18 59 ± 17 NS
Ala17Ala 59 ± 17 59 ± 19 NS
GFR (ml min-1 1.73 m-2)a
-707 G/C 77 ± 32 76 ± 32 NS
Ser9Gly 77 ± 31 76 ± 33 NS
Ala17Ala 76 ± 31 77 ± 35 NS
Urinary sodium excretion (mmol/day)a,b
-707 G/C 153 ± 68 158 ± 66 NS
Ser9Gly 151 ± 68 157 ± 66 NS
Ala17Ala 155 ± 68 153 ± 60 NS
Urinary potassium excretion (mmol/day)a,b
-707 G/C 87 ± 35 85 ± 29 NS
Ser9Gly 83 ± 34 89 ± 32 0.05
Ala17Ala 85 ± 33 93 ± 32 0.02
Data are ± SD. For abbreviations, see page 7. aPatients with ESRD excluded. bOnly
patients with no permanent medication except for insulin (n=182) were analyzed.
6.5. AT2 gene polymorphisms, diabetic
nephropathy, and blood pressure (V)
Both the functional G1675A SNP in
intron 1 and the probably non-functional
A1818T in intron 2 of the AT2 gene were
in Hardy-Weinberg equilibrium for fe-
males but could not be assessed in males
due to their X-chromosomal location.
The minor allele frequencies were 0.45
and 0.28 in females and in males 0.46
and 0.27 for the G1675A and A1818T
polymorphism, respectively. In LD
analyses, D´ = 0.98 and r2 = 0.31 in
males, and D´ = 0.97 and r2 = 0.30 in
females. The haplotypes were distributed
as GA (n = 250, 27%), GT (n = 251,
27%), AA (n = 412, 45%), and AT (n =
3, 0%) in 458 females. In 536 males they
were GA (n = 146, 27%), GT (n = 142,
26%), AA (n = 247, 46%), and AT (n =
1, 0%) for the G1675A and A1818T
polymorphism, respectively.
The G allele of the G1675A and the
T allele of the A1818T and GT haplo-
types were more common in male pa-
tients with normal renal function (GFR >
90 ml/min/1.73m2) than in those with
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impaired renal function (Table 17). The
G allele of G1675A and the T allele of
A1818T were also associated with a
higher absolute GFR value when ex-
cluding patients with ESRD, and a lower
PP and higher eGDR (Table 18).
However, none of these associations
appeared in females. In addition, no
association existed between the AT2
genotype and UAER in either males or
females (data not shown).
Table 17. Renal function compared with genotype
GFR > 90 60 GFR 90 GFR < 60 Pa
G1675A males
G 132 (61) 53 (46) 99 (51)
A 86 (39) 62 (54) 94 (49) 0.027
A1818T males
A 149 (68) 95 (83) 143 (74)
T 71 (32) 20 (17) 50 (26) 0.013
Haplotypes males
GT 71 (45) 19 (24) 50 (35)
AA 86 (55) 61 (76) 94 (65) 0.004
G1675A females
G 113 (54) 219 (54) 144 (55)
A 97 (46) 185 (46) 120 (45) NS
A1818T females
A 155 (74) 295 (73) 186 (70)
T 55 (26) 109 (27) 78 (30) NS
Haplotypes females
GT 53 (36) 97 (36) 93 (40)
AA 94 (64) 169 (64) 141 (60) NS
Data are n (%). All ESRD patients were classified as GFR < 60 ml· min-1· 1.73 m-2. adf=2
Since the G allele of the G1675A and the
T allele of the A1818T appeared to be
protective, the haplotypes were analyzed
as AA against GT. By this approach,
males with a GT haplotype showed
higher GFR and eGDR and lower PP
than did those with an AA haplotype
(Table 18). This difference remained
statistically significant after adjusting for
age. Furthermore, the G1675A allele was
independently associated with PP (r2 =
0.16, coefficient = 3.64, SE = 1.38, p <
0.01) after adjusting for HbA1c, LDL
cholesterol, BMI, and AHT. Again, no
association was seen in females.
Despite an association among the
haplotypes of the AT2 gene and renal
function and BP in males, there were no
differences in the genotypes nor in the
haplotypes of the AT2 gene to parallel
the prevalence of retinopathy or mac-
rovascular disease. Furthermore, for
either genotype or haplotypes, in either
gender, no differences were evident in
time to onset of diabetic nephropathy or
ESRD.
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7. DISCUSSION
7.1. Study subjects and their classifica-
tion
This study is part of the ongoing FinnDi-
ane Study, a comprehensive multicenter,
nationwide project with the aim to char-
acterize 25% of all adult patients with
type 1 diabetes in Finland. The patients
were recruited from the first 20 referral
centers that joined the FinnDiane study
between 1994 and 1999, and these cen-
ters covered all five university hospital
districts in Finland. All centers were
either secondary or tertial referral cen-
ters, and 19 of 20 were central hospitals.
One of the centers was a community
health care center with special interest in
the management of diabetic patients. All
attending physicians were either diabe-
tologists or nephrologists and were re-
quested to carefully complete a ques-
tionnaire regarding the medical history
of the patient; a nurse trained in diabetes
or nephrology performed the anthro-
pometric and BP measurements.
Since all central hospitals are referral
centers caring for patients with advanced
nephropathy and ESRD, a larger propor-
tion of patients with diabetic nephropa-
thy and macrovascular complications
were included in the study cohort than
had it been an entirely randomly chosen
cohort of type 1 diabetic patients. In
Finland, patients with diabetic neph-
ropathy are usually referred to the neph-
rologist at the nearest central hospital
when their serum creatinine concentra-
tion is around 150 to 200 µmol/l. As can
been seen from Table 9, the patients
with proteinuria originated from 18 of
the 20 FinnDiane centers, out of a total
of 21 central hospitals in Finland, these
patients can be considered representative
of a cross-sectional cohort of Finnish
type 1 diabetic patients with nephropa-
thy. Furthermore, 184 patients in this
study had ESRD. In 2001, according to
the Finnish Registry for Kidney Dis-
eases, there were a total of 500 patients
with ESRD due to diabetic nephropathy
(58). Consequently, this study covered
approximately 30% of all ESRD patients
in Finland, and since these patients were
recruited from 16 of these centers, they
are likely to be representative of ESRD
patients in Finland (Table 9).
Another important issue is whether
the type 1 diabetic subjects with normal
UAER constituted a representative co-
hort. An obvious trend in Finland during
the last 5 years has been to transfer dia-
betic patients with no micro- or mac-
rovascular complications from central
hospitals to primary health care. If this
had already been the case while these
patients were being recruited for this
study, one could assume that some pa-
tients would have remained under central
hospital care due to some late complica-
tion other than diabetic nephropathy.
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Consequently, if they were not true con-
trol subjects, they might dilute any po-
tential genetic differences between cases
and controls, resulting in a systematic
type II error in such an association study
(219). However, as can be seen in Table
9, only five centers provided no control
subjects. These centers had already,
except for one small center that recruited
only one classifiable patient for this
study, transferred the management of
uncomplicated type 1 diabetic patients to
primary health care, and were thus al-
most exclusively treating patients with
advanced diabetic nephropathy or ESRD.
Furthermore, one has to remember the
large proportion (45%) of patients ineli-
gible for the study (Figure 2) based on
their either having too short a duration of
diabetes or not being classified due to
too few UAERs. However, patients such
as these rarely have any late complica-
tions, clearly indicating that most of the
central hospitals at the time of this study
were in charge of all types of adult type
1 diabetic patients regardless of compli-
cation status. Selection bias for the con-
trol group is thus highly unlikely.
The microalbuminuric group is
doubtless the most heterogeneous in this
study. Microalbuminuria is considered a
strong predictor of overt nephropathy
(17-19,285), although this axiom was
recently questioned (20). Duration of
diabetes should not be neglected, since
patients with microalbuminuria and a
duration of diabetes more than 20 years
do not accurately predict development of
diabetic nephropathy (11). Those with
microalbuminuria in this study had an
average diabetes duration of 25 years.
Consequently, a substantial proportion of
these patients are at no stage likely to
develop overt nephropathy. It is also
noteworthy that none of the positive
associations found in this study involved
patients with microalbuminuria. This
may reflect the heterogeneity of the
microalbuminuric group, meaning that
those with a short duration of diabetes
are genetically more similar to those
with diabetic nephropathy in terms of
susceptibility genes, whereas those with
a long duration are genetically closer to
the control group. Unfortunately, since
the microalbuminuric group was the
smallest of the four groups (n=166), it
was impossible to further divide it by
diabetes duration.
Classification of the patients into four
groups was based on at least two of three
recent and consecutive UAER measure-
ments. All centers used timed overnight
(nU-Alb) or 24-hour (dU-Alb) urinary
collections, but almost all hospitals could
provide information from more than the
three urinary collections, which further
improved the accuracy of the classifica-
tion. One has to bear in mind that any
four groups may not remain entirely
constant over time, since both progres-
sion and regression may occur within
groups, especially for those with micro-
albuminuria. One 24-hour UAER meas-
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urement was therefore performed cen-
trally at the FinnDiane central laboratory
and was further compared to the previ-
ously measured local UAERs that were
the basis for grouping. If this result dif-
fered from that of the allocated group,
the classification was reassessed includ-
ing the centrally measured value. Reas-
sessment altered grouping class for only
seven patients (0.7%), and these were all
patients with microalbuminuria. Signifi-
cant classification bias is thus very un-
likely.
One potential confounding factor
regarding patient phenotype is the use of
AHT, especially ACE inhibitors. Use of
ACE inhibitors became commonplace in
the early 1990s after the discovery of
their renoprotective effect (41). Is then
there a risk that the control subjects (type
1 diabetic patients with normal UAER)
would have been genetically microalbu-
minuric or even proteinuric had they not
used AHT? If this were the case, it
would create a statistical type II error
that would underestimate positive re-
sults. However, such a scenario is very
unlikely for several reasons. First, only
15% of the control subjects were taking
AHT, and only 10% were treated with
ACE inhibitors. This is quite similar to
the prevalence of hypertension in the
non-diabetic background population in
Finland (286). Second, control subjects
had an average diabetes duration of 30
years. Consequently, if they were geneti-
cally susceptible to diabetic nephropathy,
they should already have developed
microalbuminuria or overt nephropathy
10 to 20 years before this study, at a time
when AHT drugs were not yet common-
place in treatment of diabetic nephropa-
thy (3). Since they had been using AHT
for only an average of 8 years, they are
likely to represent true control subjects
despite their current AHT. Third, for
many patients, several historical timed
urinary collections were available dating
back to the beginning of the 1990s and
even to the end of the 1980s with no
evidence of elevated UAER. Fourth,
each control subject had a normal serum
creatinine value. That said, had they
escaped a diagnosis of diabetic neph-
ropathy 20 years ago, they should have
had the chance to develop impaired renal
function during the years up to the time
of inclusion in this study, considering the
natural history of diabetic nephropathy
(3,59).
7.2. Methodological aspects
DNA amplification was performed with
PCR, and genotyping with the minise-
quencing method for all polymorphisms
except the Leu7Pro polymorphism in
Study III, which used a restriction en-
zyme according to a previous protocol
(133). The minisequencing method pro-
vides a numerical value which dimin-
ishes the subjectivity of interpretation
encountered in regular gel electrophore-
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sis in the use of restriction enzymes
(271,272). It is sometimes considered a
rather laborious, but a highly reliable and
a rather efficient method. One prerequi-
site is a successfully amplified PCR
product. That was the case in this study,
and genotyping failed in only less than
five patients in every study except for the
N1077S polymorphism in Study II,
where it failed in 35 patients. It is note-
worthy that these 35 patients almost
exclusively provided the DNA samples
drawn between 1994 and 1996, and
DNA concentration in these samples was
lower than in the majority of samples
collected between 1998 and 1999. How-
ever, the risk that these patients with low
DNA concentrations would have caused
genotyping errors in other polymor-
phisms is unlikely, since PCR failure
will technically result in low values in
both of the two minisequencing wells,
with a default genotyping result instead
of a spurious one (271,272). We also
evaluated the accuracy of the method in
Study I and found its reproducibility to
exceed 98%.
The candidate gene method has in
general been criticized because it may
result in an excessive number of positive
associations, often interpreted as type I
errors. Commonly, this is seen as a fail-
ure of other populations to reproduce
such positive associations (219). Fur-
thermore, the tendency to publish only
studies with positive results is a well-
known phenomenon for all complex
diseases (287,288). New guidelines re-
garding candidate gene studies have
appeared recently in one of the nephrol-
ogy journals to avoid or at least reduce
these problems in diabetic nephropathy
(289). These guidelines state that asso-
ciation studies should be published only
if the polymorphism is (1) functional, or
(2) can be reproduced in another popula-
tion or in a family-based study, or (3) is
corrected for population stratification.
Whether these criteria are appropriate
remains to be seen.
In this thesis, we studied five genes
involved in quite different pathogenetic
mechanisms. Interestingly, in all those
polymorphisms showing a positive asso-
ciation (Studies I, III, and V) there is
evidence of functionality (290-293). On
the other hand, regarding the negative
Studies II and IV, none of the polymor-
phisms were functional. It is noteworthy
that in these studies a total of three po-
lymorphisms per gene were genotyped.
Thus, had there in the near vicinity ex-
isted another functional polymorphism
important for the development of dia-
betic nephropathy, it is likely that a
positive association would have been
found due to LD (294). Thus far, neither
the positive nor the negative associations
in this study have been confirmed or
disputed, due to the short time since
publication.
Interestingly, for diabetic nephropa-
thy, the number of published candidate
gene studies has increased almost expo-
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nentially during the latter half of the
1990s. Thereafter, the number of new
studies has, however, diminished, as
depicted in Figure 4. Regarding most of
the genes, there are at most three studies
per candidate gene, as shown in the ta-
bles in section 2.5. None of the genes in
this study had previously been studied in
diabetic nephropathy except for the
RAGE gene, of which two of the three
polymorphisms were also investigated in
a Danish cohort, with a negative result
(255).
Figure 4. Number of published candidate gene studies since 1991 on gene polymor-
phism and its association with diabetic nephropathy. Data extracted from PubMed search
available at www.ncbi.nlm.nih.gov/. Search performed 15/6/04.
This present study did include only one
gene previously studied in diabetic neph-
ropathy. Interestingly enough, the ACE
I/D polymorphism has been the focus of
one-quarter of all candidate genes stud-
ies, but the impact of this polymorphism
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is still a matter of debate. Of 27 studies
of type 1 diabetic patients with neph-
ropathy involving the ACE I/D polymor-
phism, 13 showed positive associations,
and 14 were negative, as seen in Table
2. Curiously, a very similar pattern can
be seen regarding the same polymor-
phism in diabetic nephropathy in type 2
diabetes. Recently 40 studies were avail-
able on PubMed, and of these, 18
showed positive associations, with 22
negative. The question arises: What
could be the reason for such a striking
discrepancy and inconsistency? The
answer is, of course, unknown, although
several plausible explanations can be
provided.
First, it is possible that the impact of
the ACE I/D polymorphism in different
populations varies. One of two published
meta-analyses showed the I-allele to be
protective only in the Japanese popula-
tion (225), whereas the other showed no
differences between any ethnic popula-
tions, although the overall impact was
stronger in type 1 than in type 2 diabetes
(226). Second, it is possible that the
polymorphism does not contribute to the
initiation of the disease, but instead to its
progression, as shown in two recent
studies (295,296). Since the number of
prospective studies is still modest, the
final answer may not yet be known.
Many cross-sectional studies may simply
not be able to detect a possible differ-
ence, due to the heterogeneity of patients
with diabetic nephropathy. Third, a ma-
jor problem is the fact that the inheri-
tance model for diabetic nephropathy is
still unknown (188). What cannot be
ruled out is whether the impact of the
ACE I/D polymorphism represents a
minor gene effect, but of such a small
magnitude that the study populations
have thus far been simply too small to
reveal any differences between geno-
types; hence, the negative studies repre-
sent type II errors. Further, one cannot
exclude the possibility that the ACE I/D
is not a causative polymorphism, but
rather in LD with another causative gene,
as suggested by one American study
(297). Consequently, it is possible that
due to variations between LD magni-
tudes in various populations, many
studies have failed to detect the associa-
tion, since the studies have focused only
on the I/D polymorphism.
Fourth, the positive associations
could also be considered type 1 errors
due to population stratification, survival
bias, or simply to publication bias
(188,287-289). However, one cannot
overlook one important observation that
favors the ACE as a minor risk gene for
diabetic nephropathy: All positive pub-
lished association studies highlight the
DD genotype or the D allele as the risk
genotype or risk allele. Had the positive
associations been spurious, one would
expect an approximately equal number
of studies in which the II genotype or I
allele would be associated with increased
risk, since the allele frequencies are very
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close to 50%. Consequently, it seems a
waste of economic resources to perform
a multitude of small studies for one sin-
gle polymorphism, when a larger number
of well-characterized patients should be
used in the first place, and further, a
prospective design for confirmatory or
negative results.
In complex diseases, association
studies may be more fruitful if the genes
can be chosen from regions pinpointed
by linkage studies. In many other com-
plex diseases such as asthma, hyperten-
sion, and type 2 diabetes, numerous
genome-wide scans have already been
performed (298-300). For type 2 diabetes
and nephropathy there is only one pub-
lished genome-wide scan, which shows a
suggestive linkage to chromosome 7q35
in the vicinity of the aldose reductase
gene (222). However, regarding type 1
diabetes and nephropathy, still no ge-
nome-wide scans have appeared. The
arduousness of collecting a sufficient
number of informative sibling-pairs is
certainly one major reason. A long time
elapses before the renal status of type 1
diabetic sibling patients can be ascer-
tained, and the mortality for those con-
cordant for diabetic nephropathy is also
very high. Rogus et al. have, however,
suggested using discordant sibling pairs,
instead, for cases of diabetic nephropathy
(301); this should increase the number of
potential siblings considerably.
Can we expect any breakthrough in
this field in the near future? Unfortu-
nately, the reproducibility of genome-
wide scans has been remarkably low, for
example in type 2 diabetes, despite re-
cent improvements (302). Regarding
nephropathy in type 1 diabetes, the
situation might also be problematic in
comparison with many other complex
diseases, due to the relatively low ge-
netic relative risk (S-value is 2 to 2.5)
(5). It is thus possible that genome-wide
scans may be unable at this stage to
provide any major help.
7.3. Is there a genetic link between
glycemic control and diabetic neph-
ropathy?
Study I showed an association between
the functional –374 T/A AA genotype of
the RAGE promoter and UAER in pa-
tients with poor metabolic control. The
AA genotype was more common in
those with normal UAER than in those
with proteinuria. In addition, less CVD
occurred in those carrying the AA
genotype both in univariate and multi-
variate analyses. Thus, the AA genotype
may protect patients both from proteinu-
ria and from macrovascular complica-
tions.
Other data also support the view that
altered transcription of the RAGE pro-
moter region may affect susceptibility to
diabetic nephropathy and CVD. In type 1
diabetic patients, AGE levels are ele-
vated in those with nephropathy and are
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highest in those with ESRD (303). In-
vestigation of sites of AGE accumulation
in diabetic animals has revealed that
increase in RAGE expression by endo-
thelial cells may contribute to more rapid
atherosclerosis (304). Infusion of soluble
RAGE has further prevented develop-
ment of vascular disease in mice (92),
and RAGE overexpression has been
associated with an enhanced inflamma-
tory response in diabetic plaque macro-
phages (305). Furthermore, when human
RAGE is overexpressed in diabetic
transgenic mice, the result is glomerular
hypertrophy, increased albuminuria,
mesangial expansion, advanced glome-
rulosclerosis, and increased serum
creatinine—compared to levels in mice
lacking the RAGE transgene (90). These
studies imply that regulation of the re-
ceptor is a crucial event in the patho-
genesis of both micro- and macrovascu-
lar disease in diabetes. Altered transcrip-
tion induced by the –374 T/A polymor-
phism could therefore affect these proc-
esses, leading to an altered level of
RAGE and a different disease outcome,
as is evident in this study.
A linear relationship may exist be-
tween HbA1c and increased risk for dia-
betic complications (29), although a
threshold value of 8.1% has also been
suggested (30). In our study, an associa-
tion between AA genotype and protec-
tive effect for nephropathy was evident
only when HbA1c was higher than 9.5%.
A potential caveat in this study was the
fact that only 27 patients (8%) with nor-
mal UAER had such a high HbA1c value,
compared to 91 patients (28%) with
proteinuria. Our results do, however,
support the hypothesis that the –374 T/A
polymorphism affects disease risk in at
least a fraction of the patients and that
the impact of any possible protective
gene is higher when the environmental
burden is higher, in this case in those
with poor glycemic control.
The results of Study I could be criti-
cized due to the lack of a centrally meas-
ured HbA1c value. However, since all
centers participated in a national quality
assessment program, and since 75% of
the centers had identical reference val-
ues, this should have no major impact on
the study. It is also noteworthy that each
center measured HbA1c both in patients
with and without diabetic nephropathy.
Furthermore, the use of a sin-
gle—although the most recent—HbA1c
value is justified, since one single value
offers a valid estimate of average glyce-
mic control during the preceding decade
(306). In addition, spurious HbA1c values
would perhaps have been more likely to
have resulted in a type II error with a
dilution of any potential difference,
rather than in a type I error. Given this,
our results support the view of a gene-
environment interaction between RAGE
and HbA1c, which may in part explain
why some patients, despite poor glyce-
mic control, do not develop diabetic
nephropathy.
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Another interesting potential genetic
link between diabetic nephropathy and
glycemic control was evident in Study
III with respect to the association be-
tween HbA1c and the preproneuropeptide
Y. Patients heterozygous or homozygous
for the Pro7 substitution had a higher
HbA1c than did those with the Leu7Leu
genotype. The Leu7Pro was also inde-
pendently associated with HbA1c in mul-
tivariate analysis. Analyses were per-
formed both with and without the pa-
tients with ESRD, due to a potential
survival bias in the ESRD group. The
Leu7Pro has earlier been associated in
the Finnish population with carotid athe-
rosclerosis, serum LDL cholesterol lev-
els, serum triglyceride levels, and BP
(133,247,248). Since these variables are
all independent predictors for CVD, and
since mortality in ESRD is high in the
ESRD group particularly due to CVD
(307), a substantial number of patients
with ESRD and Pro7 might have been
deceased, resulting in a dilution of any
potential genetic findings. The preva-
lence of Pro7 was higher in those with
proteinuria than in those with ESRD,
although the difference was not signifi-
cant.
Can the difference in HbA1c between
genotypes be explained by impact on
insulin sensitivity induced by the
Leu7Pro? A recent study in the Finnish
population showed no association be-
tween Leu7Pro and insulin sensitivity,
insulin secretion or glucose metabolism
(308). One has to bear in mind, however,
that that study was performed in healthy
control subjects, whereas our study com-
prised type 1 diabetic patients suffering
various stages of renal complications. In
addition, eGDR was lower and the daily
insulin dose higher in female patients
with the Pro7 substitution, perhaps due
to their more pronounced insulin resis-
tance. Moreover, the possible link be-
tween the Leu7Pro, insulin sensitivity,
and HbA1c is supported by the fact that
when the dose was adjusted for HbA1c
the association between Leu7Pro geno-
type and insulin dose disappeared. A
potential link may also be the impact of
NPY on energy homeostasis. In experi-
mental studies, it appears that elevated
NPY expression in the hypothalamus
contributes to development of obesity
and its related phenotypes (132). This is
further supported by the fact that our
patients with Pro7 also had a higher
BMI. Our results may thus indicate that
NPY Leu7Pro is involved in regulation
of glycemic control, although the
mechanisms call for further investiga-
tion.
7.4. The glomerular filter and protein-
uria in diabetic nephropathy
Little was known about the glomerular
slit-diaphragm until the nephrin protein
was described (178) and the nephrin
gene (NPHS1) cloned (309) a few years
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ago. The latter study showed that muta-
tions in the nephrin gene, which lead to a
total loss of the nephrin protein from the
slit diaphragm, were responsible for the
Finnish type of congenital nephrosis in
infants already showing massive prote-
inuria at birth (310). Therefore, in Study
II, we hypothesized that common poly-
morphisms could also lead to a minor
disturbance in the nephrin protein, with a
subsequent increase in the susceptibility
to proteinuria in a diabetic milieu.
No association was, however, appar-
ent between these three polymorphisms
in the coding region of the nephrin gene
and diabetic nephropathy or any vari-
ables related to renal function. The re-
sults were also negative when the poly-
morphisms were analyzed separately, or
when genotype combinations were used.
On the other hand, this finding does not
yet entirely rule out the role of the neph-
rin gene in the pathogenesis of diabetic
nephropathy, since thus far only the
coding region and part of the promoter
region have been studied. A major im-
pact of the gene on diabetic nephropathy
is still unlikely, since the polymorphisms
were evenly distributed over the exons. It
is thus probable that any possible causa-
tive polymorphism in the intron region
or promoter region had been in LD with
those studied.
Interestingly, the nephrin gene and
nephrin protein have been connected in
experimental studies with early changes
in diabetic nephropathy such as loss of
the permeability barrier of the glomeruli
(184). Leakage of nephrin into the urine
has in a recent human study also been
suggested as an early marker of diabetic
nephropathy (187). Furthermore, block-
ade of the AT1 and ACE have reduced
nephrin expression in a diabetic milieu
(180,182); this may reveal a potential
link between the gene and the RAAS. In
addition, it is also possible that a defi-
ciency in the podocyte layer complex
consisting of nephrin, CD2-associated
protein (CD2AP), podocin, and actin
cytoskeleton is responsible for functional
or morphological changes in the slit-
diaphragm in human glomerular diseases
other than the Finnish type of congenital
nephrosis (186). Although nephrin and
CD2AP both bind to actin, it remains
unknown known whether nephrin binds
directly to actin or whether CD2AP
serves as an adapter to this binding site
(311). What also cannot be ruled out is
whether any yet unidentified proteins are
involved in this complex. Data on poten-
tial variations in the genes coding these
proteins in the podocyte layer are still
very scarce, although at least mutations
in the podocin gene have been reported
to lead to focal segmental glomeruloscle-
rosis (312). In addition, a polymorphism
in the caldesmon gene coding the actin
cytoskeleton has been associated with
diabetic nephropathy (260). It is thus
possible in diabetic nephropathy that it is
not the nephrin gene itself, but rather the
genes regulating the nephrin attachment
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to the podocyte layer entity that may
contribute to the proteinuric mecha-
nisms.
7.5. The role of dopamine receptors in
diabetic nephropathy
The dopamine system is a potential
modulator of renal function and BP
(125), although current knowledge con-
cerning its influence on humans subjects
is scarce (313). Of the five known do-
pamine receptors, the DRD3 receptor is
expressed in the kidney (314). Interest-
ingly, disruption of this receptor in mice
has resulted in significant elevation of
BP levels and higher renin activity (128).
Further experimental data show that
nitecapone, an inhibitor of the dopamine
metabolizing enzyme catechol-O-methyl
transferase, is a potential protective ther-
apy against development of diabetic
nephropathy (315). Type 2 diabetic pa-
tients with advanced nephropathy have
also shown decrease in renal synthesis of
dopamine (127).
Study IV uncovered no association
between the genotypes or haplotypes of
the polymorphisms in the DRD3 gene
and BP levels, kidney function, urinary
sodium or potassium excretion or stage
of nephropathy, however. Stratifying for
gender did not alter the negative results.
On the other hand, this study cannot
entirely exclude the role of the DRD3
gene in regulation of BP levels or patho-
genesis of diabetic nephropathy, al-
though this seems unlikely for several
reasons. First, LD between a causative
polymorphism and one of the polymor-
phisms studied has been probable, espe-
cially regarding the promoter region,
because of the short distances involved
(294). Second, the power in this cohort
was sufficient to detect a major or mod-
erate effect. Third, a negative association
between the Ser9Gly polymorphism and
hypertension has already been reported
(316). Other dopamine receptor genes
should thus be investigated, because
recent data show, in mice, a disruption of
the dopamine D2 receptor (DRD2) to
result in a sodium-dependent increase in
BP (317). Furthermore, two human
studies have reported an association
between a polymorphism in the coding
region of this gene and elevated BP
(318,319). In addition, the dopamine D1
receptor (DRD1), another gene among
the D1-like receptors, has been associ-
ated with hypertension (320).
7.6. Is the AT2 gene a link between
renal function, blood pressure, and
gender in diabetic nephropathy?
In Study V, the AA haplotype of the
G1675A and A1818T polymorphisms in
the AT2 gene was in male subjects asso-
ciated with decline in renal function and
higher PP; furthermore, the G1675A was
also associated with PP in a multivariate
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analysis. It is noteworthy that no differ-
ences were evident in females between
the genotypes or haplotypes and these
variables. This finding raises the ques-
tion whether there is a true gender differ-
ence in the pathogenesis of diabetic
nephropathy.
Diabetic nephropathy (3) and renal
failure in general (217) seem to be more
common in males, although epidemiol-
ogical data are surprisingly scarce re-
garding this matter. Recent longitudinal
data from a Danish cohort supports a
male preponderance for diabetic neph-
ropathy, since male sex was an inde-
pendent predictor for microalbuminuria
during that study’s 18-year follow-up
(218). As can be seen in Table 8, the
male proportion of our study population
is significantly higher in all groups ex-
cept for those with normal UAER. A
similar male predominance can be seen
in the entire FinnDiane cohort, which
currently consists of more than 4000
type 1 diabetic patients (unpublished
data). This finding is also in line with
that of the Finnish Registry for Kidney
Diseases from 2001, wherein 59% of all
patients with renal replacement therapy
were males (58). Although these figures
support the notion that diabetic neph-
ropathy is more common in males, it is
possible that the true proportion of males
may be even higher than observed in
these studies. Significantly higher car-
diovascular mortality is, in fact, a well-
known phenomenon in males (216,321),
and male patients with ESRD may have
died earlier from CVD; one would there-
fore have expected to find more females
with diabetic nephropathy. In some
studies, there seems to be a true male
preponderance in diabetic nephropathy,
although it is possible that this finding
may instead reflect a higher male pre-
ponderance in renal disease in general
(58), making it not a phenomenon spe-
cific only to diabetic nephropathy.
Is the association between AA
haplotype and GFR seen in Study V
specific for diabetic nephropathy, or does
this association reflect a more rapid
decline in renal function in general? This
study introduced the GFR according to
the Cockcroft-Gault formula as a surro-
gate measure for kidney function for
several reasons. GFR is a more sensitive
measurement of decline in kidney func-
tion than is serum creatinine (269), and it
is also more reliable than timed creatin-
ine clearance measurements, which tend
to underestimate hyperfiltration and
overestimate low GFR (322). Further-
more, timed creatinine clearance is prone
to error during urine collection. The use
of GFR instead of the four UAER groups
in diabetic nephropathy to assess renal
complication status may certainly be
criticized. However, one has to bear in
mind that not all patients with diabetic
nephropathy will develop nephrotic
albuminuria (323), and that some pa-
tients with microalbuminuria will never
progress to overt nephropathy, and some
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will regress to normal UAER (20). Divi-
sion into groups according to UAER is
also arbitrary, whereas decrease in GFR
approaches linearity with a relentless and
permanent decline in renal function
(324).
We found a positive association with
the AA haplotype both when GFR was
categorized according to guidelines by
the National Kidney Foundation (325)
and when GFR was analyzed as a con-
tinuous variable. The former analysis
enabled inclusion of patients with ESRD,
since all ESRD patients must have had a
GFR < 60 ml· min-1· 1.73 m-2 prior to
their renal replacement therapy. The
latter analysis excluded patients with
ESRD, since a majority had had a renal
transplant, and their present GFR would
naturally not be informative. The possi-
bility that the AA haplotype is detri-
mental for renal function in general,
independent from diabetic nephropathy,
is supported by the fact that no associa-
tion was evident between the genotypes
and UAER, neither when UAER was
analyzed as a continuous variable nor
when it was categorized into the four
UAER groups. Furthermore, we ob-
served no association after adjusting for
age between the AA haplotype and reti-
nal laser treatment or macrovascular
complications. In addition, no associa-
tion was apparent between the GFR and
any of the polymorphisms in Studies I-
IV in a post hoc analysis. This supports
the fact that the AT2 gene is perhaps not
involved in the initiation or progression
of diabetic nephropathy per se, but rather
in the rate of decline in renal function in
general.
Interestingly, the AA haplotype of
the AT2 gene was also associated with
PP in males, but after adjustment for age
not with SBP or DBP. The RAAS is a
key player in BP control (326) and also
may be involved in the progression of
renal disease in diabetes (327). Increase
in PP appears to occur 20 years earlier in
type 1 diabetic subjects than in non-
diabetic subjects, regardless of their renal
status, according to our recent study
(328). This probably reflects the prema-
ture aging of the arterial tree due to hy-
perglycemia, since the duration of dia-
betes appeared to be a strong determi-
nant. The impact of the AT2 gene on BP
is supported by studies in non-diabetic
subjects, in which positive associations
have appeared in males between the AT2
gene and both hypertension (329) and
left ventricular hypertrophy (330,331). It
is unclear whether these studies included
PP in their analysis. If so, it is still possi-
ble that no association would have been
detected, since the study subjects were
non-diabetic with perhaps a too-slow
increase in arterial stiffness for any effect
of the AT2 gene to be detectable. In our
study, the 1675A allele was independ-
ently associated with PP in males after
adjustment for standard risk factors,
although the prevalence of hypertension
and SBP and DBP did not significantly
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differ between the genotypes and haplo-
types. Neither was the AT2 gene associ-
ated with CHD after adjustment for age.
Impact of the AT2 gene on CHD may,
however, be highest in those with hy-
pertension. In a study of non-diabetic
males, the 1675A allele was associated
with excess risk among those with sys-
tolic hypertension, whereas CHD risk
was independent of AT2 genotype among
normotensive individuals (332). Unfor-
tunately, the lack of power in our cohort
will make further testing of this hypothe-
sis impossible.
The gender-specific association be-
tween the AA haplotype of the X-
chromosomal AT2 gene and renal func-
tion and also PP suggests recessive in-
heritance. If this model is correct, a
positive association should have been
evident also in comparison of females
homozygous for the AA haplotype with
those homozygous for the GT haplotype.
However, only a non-significant trend
toward a higher PP and a decreased GFR
occurred in females homozygous for the
AA haplotype. This negative association
may also be due to the lack of power,
since we had only 36 female patients
homozygous for the AA haplotype.
Thus, the question of whether associa-
tion with renal function and PP in males
is due to the X-chromosomal location of
the A T 2 gene, or whether the X-
chromosomal location is merely coinci-
dental remains unanswered; it certainly
warrants further studies.
7.7. Are there genetic mechanisms in
common behind diabetic nephropathy
of type 1 and of type 2 diabetes?
This study deals exclusively with the
diabetic nephropathy of type 1 diabetic
patients. The question does arise whether
any of the positive or negative gene
associations found can be generalized
and considered applicable in type 2 dia-
betes, as well. Before this question can
be answered, it is important to compare
not only the clinical phenotype but also
the morphological lesions seen in the
two disorders. Microalbuminuria in type
1 diabetes is in most cases a clinical sign
of incipient diabetic nephropathy (17-
19), although its natural clinical course
may range from rapid to rather slow
progression to ESRD. The morphologi-
cal lesions are thickened basement mem-
branes (63), mesangial expansion, and
narrowing of capillary lumens (64).
Ultimately, the glomeruli are destroyed,
and the patient develops profuse protein-
uria and a relentless decline in renal
function. Microalbuminuria can therefore
be considered a rather pathognomonic
sign of increased risk for overt diabetic
nephropathy, although its predictive
value regarding the velocity of disease
progression may be rather low (11).
Microalbuminuria in type 2 diabetes
is a much more complex issue, and is
often already present at the time of the
diagnosis (333,334). This is hardly ever
the case in type 1 diabetes. Moreover, it
70
is well known that the level of microal-
buminuria can remain constant for years
in some patients with no signs of pro-
gressive renal disease. In such cases,
microalbuminuria is usually found with-
out any diabetic lesions in the retina,
whereas microalbuminuria in type 1
diabetes is nearly always associated with
diabetic retinopathy (112). Interestingly,
some proportion of patients with type 2
diabetes also present with a clinical
course that resembles that of type 1 dia-
betic patients, i.e., progressive proteinu-
ria and decline in glomerular filtration
rate, as well as other diabetic microvas-
cular complications. Such patients are
perhaps genetically similar to those with
type 1 diabetes. Such a view is actually
supported by the morphological picture
of the renal lesions of type 2 diabetes
(335). Approximately 30% of the type 2
diabetic patients with microalbuminuria
have morphological lesions typical of
diabetic nephropathy, as seen in type 1
diabetes. However, another 30% of these
patients with microalbuminuria show
rather normal kidney morphology de-
spite a degree of microalbuminuria
similar to that of the other group. The
remaining 40% present rather unspecific
lesions such as advanced arteriolohyali-
nosis, interstitial fibrosis and peculiar
glomerular changes, where some glome-
ruli appear totally normal while others
are totally destroyed. Given the complex
nature of microalbuminuria in type 2
diabetes, it has been suggested that mi-
croalbuminuria in a large proportion of
these patients is a result of generalized
endothelial dysfunction rather than of
renal injury (336).
Microalbuminuria and even proteinu-
ria thus seems to be an important marker
not only of advanced diabetic vascular
disease but also of nephropathy (337).
Consequently, it may be hazardous to try
to generalize findings of genetic associa-
tions found in type 1 diabetes to all cases
of type 2 diabetes. However, it does
seem plausible to assume that those with
type 1 diabetes and type 2 diabetes with
a similar clinical course and similar
morphological lesions represent the same
disease and the same pathogenetic
mechanisms. If this view is true, it also
highlights the importance of careful
characterization of type 2 diabetes pa-
tients for genetic studies.
The next question is whether the
genes involved in the pathogenesis of
diabetic nephropathy in type 1 diabetes
are specific for this trait, or whether the
same genes lead to an increase in sus-
ceptibility for nephropathy in type 2
diabetes as well, or even in the suscepti-
bility for type 2 diabetes. Further, could
genes regulating BP, lipid levels or insu-
lin sensitivity be the common denomi-
nators of type 2 diabetes or nephropathy
of type 2 diabetes as well as of type 1
diabetes? The NPY Leu7Pro polymor-
phism from Study III has been associated
with several variables common for the
type 2 diabetic phenotype such as lipids
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(133,247,248), BP (247), and even reti-
nopathy (135). Since this polymorphism
was associated not only with proteinuria
but also CHD, as shown in Study III, it is
possible that the common denominators
of diabetic nephropathy in type 1 and
type 2 diabetes are actually genes that
contribute to atherosclerotic mecha-
nisms. This is supported by the fact that
in two different patient cohorts, Leu7Pro
was also associated with carotid athero-
sclerosis (247,249).
Furthermore, endothelial dysfunction
and premature atherosclerosis may be a
consequence of alteration of the AT2
gene function, as shown in males in
Study V. Thus, the increased PP and
lower eGDR found in those patients with
the AA haplotype may reflect a more
rapid atherosclerosis and, although not
studied here, this may be similar to the
situation in patients with type 2 diabetes.
It is thus possible that both the NPY and
AT2 genes can be involved in mecha-
nisms contributory to the type 2 diabetic
phenotype and to diabetic nephropathy.
On the other hand, certainly genes
exist that may not have anything in
common with variables constituting the
type 2 diabetic phenotype, such as the
nephrin gene in Study II. In the case of
nephrin, it is interesting that the nephrin
gene is also expressed in the pancreas
and could possibly affect  cell function
(338), although its major function is
related to the slit-diaphragm. It is there-
fore worthwhile to test such genes in
type 2 diabetic patients as well before
entirely rejecting them as candidate
genes for diabetic nephropathy.
Given the rather large number of
candidate gene studies in diabetic neph-
ropathy, the question arises whether
there is overlapping of the genes studied
for diabetic nephropathy in type 1 and
type 2 diabetes. In addition to the genes
in Studies II to V, there are at least 17
genes studied only in type 1 diabetes. On
the other hand, at least 20 genes are
studied exclusively in type 2 diabetes, as
can be seen in Table 19. Interestingly, in
type 2 diabetes, 16 of the 20 genes
showed positive associations, whereas
only 3 of 17 gave positive associations in
type 1 diabetes. Several possible expla-
nations for this striking discrepancy
exist. As previously discussed, diabetic
nephropathy in type 2 diabetes is a het-
erogeneous disease (335), and it is possi-
ble that a higher number of genes are
involved in diabetic nephropathy in type
2 diabetes than in type 1. On the other
hand, this lead to the theory that the
genes in type 2 diabetes have merely a
minor effect; if this is the case, it is
questionable whether these studies have
had enough power to demonstrate any
true positive association, since many of
the studies contained a markedly small
number of patients. In only two of the
studies, in those concerning the matrix
metalloprotease 9 gene (M M P 9 )
(339,340) and peroxisome proliferative
activated agonist receptor gamma gene
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Table 19. Genes studied for diabetic nephropathy in only one of the diabetes subtypes
Gene Potential mechanism Positive association
Reference
No association
Reference
Genes studied exclusively in type 2 diabetic patients
Chymase BP (433)
Kallikrein 3 BP (434)
Solute carrier family 12 member 3 BP (435)
a2b1 integrin CVD (436)
Adrenomedullin CVD (437)
G Protein IIIa CVD (438)
Lipoprotein lipase CVD (439)
HFE (hemochromatosis) DIAB (440)
Mitochondrial tRNA LeuUUR DIAB (441)
PPAR2 DIAB (341,342)
Glutathione S-transferase M1 GF (442)
Interleukin-6 GF (443)
Matrix metalloprotease 9 GF (339,340)
TGF- stimulated clone 22 GF (444)
GFPT2 GM (445)
Manganese superoxide dismutase GM (446)
Chemotactic cytokine receptor 5 IMMUN (447)
CTLA4 (IDDM12) IMMUN (448)
LECAM-1 IMMUN (449)
RANTES gene promoter IMMUN (447)
Genes studied exclusively in type 1 diabetic patients
Alpha adducin BP (236)
ATP1 A1 BP (407)
Epithelial sodium channel BP (409)
SA BP (414)
von Willebrand factor CVD (420)
Werner helicase CVD (390)
ENPP1 (PC-1) DIAB (450) (380,429)
Nuclear factor kappa B GF (432)
AGE-R1, AGE-R2, AGE-R3 GM (255)
RAGE GM (255)
Caldesmon GS (260)
Collagen IVA1 GS (430)
Decorin GS (258) (390)
Complement C4 IMMUN (421)
Renin RAAS (229)
BP = blood pressure, CVD = cardiovascular disease, DIAB = diabetes, GF = growth
factors and cytokines, GM = glucose metabolism, GS = glomerular structure, IMMUN =
immunology.
ATP1A = ATPase, Na+/K+ transporting gene, CTLA4 = cytotoxic T-lymphocyte-
associated protein 4 gene, ENPP1 = alpha 1 polypeptide gene, ectonucleotide pyrophos-
phatase / phosphodiesterase 1 gene, GFPT2 = glutamine fructose-6-phosphate transa-
minase 2 gene, LECAM-1 = leukocyte-endothelial cell-adhesion molecule 1 gene,
PPAR2 = peroxisome proliferative activated agonist receptor gamma gene.
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(PPAR2) (341,342), could such an asso-
ciation be confirmed in another popula-
tion. It can be argued that some of the
positive associations represent a type I
error due to population stratification
(343) or a publication bias. It is also
quite striking that for none of the genes
in type 2 diabetic patients were any con-
tradictory results published; this has been
commonplace for association studies in
complex diseases and in regard to the I/D
polymorphism of the ACE gene. It is
further interesting that only one con-
flicting study concerned type 1 diabetic
cohorts. Whether there are indeed fewer
genes involved in diabetic nephropathy
in type 1 diabetes, or whether the fre-
quent positive associations in type 2 are
spurious, remains to be elucidated.
7.8. Concluding remarks and future
prospects
Genetic factors in diabetic nephropathy
have been studied for 15 years (192), but
the genetic background of this devastat-
ing complication is still far from known.
Several major problems complicate the
unraveling of the genetics in this disease.
It is likely that the S value of 2 to 2.5 in
diabetic nephropathy is lower than in
many other complex diseases (5). Even
the inheritance pattern is still unresolved,
since it is not known whether the disease
is due to a few major genes or to several
minor ones (188). If the latter is true, it is
even possible that genes with minor
effects have already been studied, but
due to negative results they have been
denied publication. Successfully pub-
lished negative results could, on the
other hand, result from too-small sample
sizes. Furthermore, mortality is still very
high in these patients despite intensified
treatment and improved prognosis (59).
This also makes it very difficult to re-
cruit a sufficient number of sibling pairs
to gain enough power for genome-wide
scans. However, study of large numbers
of type 1 diabetic sibling pairs concor-
dant or discordant for diabetic neph-
ropathy could improve the identification
of genomic regions harboring the true
susceptibility genes for diabetic neph-
ropathy. Whether there will ever be a
sufficient number of informative sibling
pairs available from a homogenous
population remains to be seen. One of
the attempts of the FinnDiane study is to
achieve such a goal. Moreover, one has
to bear in mind that the genetics of type
1 diabetes and of hypertension, both with
higher S values than in diabetic neph-
ropathy, have been studied for a longer
period of time, but still the genetics of
these traits are also far from unrevealed.
On the other hand, the human ge-
nome has recently been sequenced
(344,345), giving us reason to expect
that the specific functions of many genes
will be known within 10 to 20 years.
This will make it possible to investigate
genes that are entirely new, and at this
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stage still unknown that may be impor-
tant for diabetic complications. Geno-
typing technology is also advancing with
remarkable speed. More than 100 000
genotypes can today be determined faster
than could 1 000 when this study was
initiated. Computer science and bioin-
formatics are making rapid progress, and
collaboration with biomedicine grows
more intense. Of perhaps even greater
importance, even larger study popula-
tions are available and, above all, they
are more carefully characterized than
before. The FinnDiane study is one ex-
ample and is already at this point one of
the largest in the world when it comes to
studying diabetic complications. Inter-
national collaboration and networking
will be crucial in increasing genetic
power still further.
The present study has contributed to
our current knowledge by investigating
five genes from very distinct biochemi-
cal pathways and their potential associa-
tions with diabetic nephropathy and
other late complications in type 1 diabe-
tes. All studies were association studies,
but they can doubtlessly contribute to
building strategies for future studies.
Polymorphisms in the RAGE gene
(Study I) could in part explain why some
patients despite poor glycemic control do
not develop diabetic nephropathy. This
gene should be further studied in other
populations and especially in a prospec-
tive study design. Other AGE-receptor
genes should be explored further, and in
addition, serum AGEs should be meas-
ured and studied in relation to the genet-
ics of the AGE cascade. Polymorphisms
in the nephrin gene (Study II) had not
been previously studied in diabetic pa-
tients. Since it seems unlikely that this
gene contributes to diabetic nephropathy,
studies should rather be focused on other
genes regulating the function of the
nephrin protein or other components of
the glomerular filter.
In addition to the novel association
between HbA1c and the Leu7Pro poly-
morphism of the preproneuropeptide Y
(Study III), these findings support find-
ings indicating involvement with en-
hanced atherosclerosis. There are, how-
ever, still no prospective data regarding
the Leu7Pro, and studies in other popu-
lations regarding atherosclerosis and its
related traits are almost completely
lacking. Further functional studies are
needed to confirm whether the Leu7Pro
itself or another polymorphism in LD is
responsible for these findings. Study IV
was the first to explore the impact of a
gene in the dopamine system with re-
spect to diabetic late complications. The
negative association of the DRD3 gene
with diabetic nephropathy and BP levels
should instead warrant other dopamine
receptor studies that may be involved in
BP-regulating mechanisms. The AT2
gene (Study V) had also not been studied
previously in diabetic complications.
This gene may contribute to the male
predominance in diabetic nephropathy
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and kidney disease in general, and it may
be involved in premature aging of the
vessel walls. The impact of this gene
needs to be confirmed in prospective
studies and in other populations as well,
and the function of the gene and its in-
teractions with other genes of the RAAS
need to be further clarified.
Doubtless, the results of this thesis
are a mere beginning, and the truly im-
portant results will be seen when pro-
spective data are available for all candi-
date genes that show a positive associa-
tion in a cross-sectional design. How-
ever, learning the genetic mechanisms
for a disease would be worth nothing if
the patient did not gain from this knowl-
edge. It is quite clear that a huge benefit
would derive from identifying those at
increased genetic risk at a much earlier
stage in order to provide these patients
with all available treatment to avoid
complications. Economic resources
should be directed toward these high-risk
patients. A majority of them would
probably be motivated to further improve
their glycemic control, were they only
aware of their increased risk profile.
Even more importantly, when the genetic
mechanisms and pathogenesis of diabetic
nephropathy are identified, there will be
better prospects for developing entirely
new treatment methods. The question is
surely not so much whether the mystery
behind diabetic nephropathy will be
solved one day, but rather when.
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8. MAIN CONCLUSIONS OF THE STUDY
1. Association between the AA genotype of the RAGE –374 T/A polymorphism and
CVD as well as albumin excretion in type 1 diabetic patients with poor glycemic
control suggests a gene-environment interaction in development of diabetic neph-
ropathy and cardiovascular complications.
2. No support was found in type 1 diabetic patients for involvement of the coding
region of the nephrin gene in the pathogenesis of diabetic nephropathy.
3. Leu7Pro polymorphism of the preproneuropeptide Y may contribute to the
susceptibility to diabetic nephropathy and coronary heart disease in type 1
diabetic patients, possibly by influencing glycemic control and lipid metabolism.
4. No evidence appeared for involvement of the dopamine D3 receptor gene in
pathogenesis of diabetic nephropathy or in blood pressure levels in type 1 diabetes.
5. A gender-dependent association between the AT2 gene and kidney function as well
as between the gene and premature aging of the arterial tree appeared in male type 1
diabetic patients.
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9. POPULÄRVETENSKAPLIG
SAMMANFATTNING PÅ SVENSKA
Omkring en tredjedel av samtliga patien-
ter med typ 1 diabetes, som tidigare be-
nämnts ungdomsdiabetes, utvecklar en
framskridande njursjukdom som under
förloppet av 10-15 år helt förstör njurar-
na med dialysbehandling eller eventuell
njurtransplantation som följd. Dessa pa-
tienter innehar en 40-faldigt förhöjd risk
för hjärtinfarkt, vilket är orsaken till att
mortaliteten är ungefär 50% inom de när-
mast påföljande 5 åren då dialysbehand-
lingen påbörjats.
Orsakerna till njursjukdomen är i
stort sett okända. En förutsättning för
sjukdomen är att blodsockernivån under
en längre tid är över det normala. Man
vet även att ett förhöjt blodtryck ökar
sjukdomsrisken och ger upphov till att
sjukdomen framskrider snabbare. Det
finns dock patienter som i årtionden haft
mycket höga blodsockervärden utan att
de utvecklar någon som helst njurskada.
Å andra sidan finns det patienter som
trots tillfredsställande blodsockerbalans
kan utveckla en rätt snabbt framskridan-
de sjukdom. Detta tyder på att genetiska
orsaker påverkar om man insjuknar eller
inte. Det kanske mest övertygande be-
visen för ett genetiskt påbrå är de sys-
konparstudier, som påvisat att risken för
att en person med diabetes kommer att
insjukna i njursjudomen, är betydligt
högre, om det i samma familj från
tidigare finns ett syskon med diabetisk
njursjukdom.
Det är uppenbart att diabetisk njur-
sjukdom, i likhet med astma och blod-
tryckssjukdom, hör till de komplext ned-
ärvda sjukdomarna, där en samverkan
mellan omgivningen och den genetiska
läggningen bestämmer huruvida man
insjuknar och hur snabbt sjukdomen fort-
skrider. Det har dock visat sig vara
mycket mödosamt att hitta genvaria-
tioner som antingen utsätter eller skyddar
patienten för dylika sjukdomar, eftersom
det kan vara fråga om ett stort antal
genvariationer vars enskilda verkan är
rätt liten. Det finns två huvudstrategier. I
den första utgår man ifrån möjligast
många syskonpar och genomsöker samt-
liga kromosomer i hopp om att finna
områden som inhyser gener med varia-
tioner som kunde tänkas bidraga till
sjukdomsprosessen. Denna metod har
ännu inte utförts inom diabetisk njur-
sjukdom vid typ 1 diabetes.
I den sk. kandidatgenstrategin utgår
man ifrån kända gener vars genvaria-
tioner (polymorfismer) kunde påverka
sjukdomsmekanismerna. I en associa-
tionsstudie jämför man i detta fall
huruvida en dylik polymorfism före-
kommer oftare hos de som har utvecklat
njursjukdomen jämfört med en kontroll-
grupp bestående av typ 1 diabetiker som
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inte har några som helst tecken på
njursjukdom trots långvarig diabetes.
Denna strategi har används i denna dok-
torsavhandling, där genpolymorfismer i
fem gener undersökts. Beträffande
RAGE-genen, som kodar en sockeräm-
nesomsättningsreceptor, observerades en
association mellan en funktionell poly-
morfism och en skyddande effekt visavi
diabetisk njursjukdom hos patienter med
påfallande dålig sockerbalans. I NPY
genen, som kodar en neurotransmitter,
hittades däremot en association mellan
en funktionell polymorfism samt såväl
diabetisk njursjukdom, triglyceridhalt,
sockerbalans, som kransartärsjukdom. I
AT2 genen, som befinner sig på X-
kromosomen hittades en association
mellan en polymorfism och njurfunk-
tionenen samt blodtrycket hos män,
vilket betyder att genen eventuellt delvis
skulle kunna förklara varför njursjuk-
domen är vanligare hos män. Två av
generna i denna studie uppvisade där-
emot inga samband alls med någon av de
undersökta variablerna.
Det bör avslutningsvis poängteras att
samtliga positiva associationer ännu
kräver uppföljningsstudier för att man
skall kunna dra några definitiva slut-
satser angående orsak och verkan. Om de
genetiska orsakerna till diabetisk njur-
sjukdom skulle identifieras, kunde detta
möjliggöra ett tidigt ingripande och en
fokusering av de ekonomiska resurserna
på just de patienter som har gener som
utsätter dem för sjukdomen. Detta kunde
på sikt leda till att sjukdomen i framtiden
helt kunde förebyggas eller åtminstone
uppskjutas.
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10. YLEISTIETEELLINEN YHTEENVETO SUOMEKSI
Kolmasosalle kaikista tyypin 1, eli nuo-
ruustyypin diabetesta sairastaville poti-
laille, kehittyy etenevä munuaistauti,
joka 10-15 vuodessa tuhoaa munuaiset ja
johtaa potilaan dialyysihoitoon tai munu-
aisensiirtoon. Näillä potilailla on 40-
kertainen riski sairastua sydäninfarktiin
ja heidän kuolleisuutensa dialyysihoidon
alkamisajankohdasta lähtien on noin
50% viidessä vuodessa.
Diabeettisen munuaistaudin perim-
mäiset syyt ovat yhä tuntemattomat.
Ehkä tärkein syy sairastumiseen on
pitkäaikainen normaalia korkeampi ve-
rensokeritaso. Lisäksi tiedetään että
korkea verenpaine lisää sairastumisriskiä
ja nopeuttaa taudin etenemistä. On
kuitenkin potilaita, joilla on vuosikym-
meniä ollut hälyttävän korkeita veren-
sokeriarvoja ilman että munuaisiin ke-
hittyy minkäänlaisia vaurioita, ja toi-
saalta potilaita, jotka varsin hyvästä ve-
rensokeritasapainosta huolimatta kehittä-
vät nopeasti etenevän munuaistaudin.
Tämä viittaa vahvasti siihen, että perin-
tötekijöillä on osuutta sairastuvuuteen.
Vahvimmin perintötekijöiden osuutta tu-
kevat todisteet löytyvät tutkimuksista,
joissa osoitetaan diabetesta sairastavalla
nuoremmalla sisaruksella olevan kohon-
nut riski sairastua munuaistautiin, jos
vanhemmalla sisaruksella on jo todettu
tämä tauti.
On selvää, että diabeettinen munuais-
tauti, samoin kuin esimerkiksi astma ja
verenpainetauti, kuuluvat nk. moniteki-
jäisiin tauteihin, joissa ympäristövaiku-
tusten ja perintötekijöiden vuorovaikutus
yhdessä määräävät sairastuvuuden ja tau-
din etenemisnopeuden. Koska taudin
taustalla voi olla useita altistavia perin-
tötekijöitä joissa yksittäisen tekijän vai-
kutus on pieni, on osoittautunut erittäin
vaikeaksi löytää sekä potilaita altistavia
että suojaavia perintötekijöitä. Kyseisten
tekijöiden löytämiseksi on olemassa
kaksi päästrategiaa. Näistä ensimmäi-
sessä tutkitaan potilaiden perimää mikro-
satelliitti-markkereilla jotta voitaisiin
löytää sairaudelle altistavat kromoso-
maaliset alueet. Tällaista koko genomia
kattavaa analyysiä ei vielä ole tehty
tyypin 1 diabeettista munuaistautia sai-
rastavilla potilailla.
Ehdokasgeenimenetelmässä lähtö-
kohtana puolestaan on tutkia jo aiemmin
tunnistettuja, mahdollisesti munuaistauti-
prosessin laukaiseviin tekijöihin vaikut-
tavia geenivaraatioita. Tällä menetel-
mällä tutkitaan esiintykö jokin geeni-
variaatio useammin diabeettistä munu-
aistautia sairastavilla potilailla kuin
kontrolliryhmällä, joka koostuu diabetes-
potilaista, joilla ei ole minkäänlaisia
munuaistaudin merkkejä taudin pitkästä
kestosta huolimatta. Tässä tutkimuksessa
tutkittiin viiden geenin variaatioita. So-
keriaineenvaihduntareseptoria koodaa-
vassa RAGE-geenissä todettiin yhteys
(assosiaatio) erään toiminnallisen vari-
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aation ja diabeettiseltä munuaistaudilta
suojaavan vaikutuksen välillä niillä poti-
lailla, joilla oli erityisen huono veren-
sokeritasapaino. NPY-geenissä, joka koo-
daa erästä hermovälittäjäainetta, löy-
dettiin yhteys toiminnallisen variaation
sekä diabeettisen munuaistaudin, trigly-
seridipitoisuuden, verensokeritasapainon
sekä sepelvaltimotaudin välillä. X-kro-
mosomissa sijaitsevan AT2 geenin to-
dettiin assosioituvan toiminnalliseen
geenivariaatioon sekä munuaistoimin-
taan ja verenpainetasoon miehillä, mikä
voisi viitata nimenomaan miesten kor-
keampaan sairastuvuuteen valtimokovet-
tumatautiin. Kahden geenin kohdalla ei
löydetty minkäänlaista assosiaatiota tut-
kittuihin tekijöihin.
Lopuksi on korostettava, että kaikki
todetut assosiaatiot vaativat seurantatut-
kimuksen mahdollisten syy-seuraussuh-
teiden varmistamiseksi. Diabeettisen
munuaistaudin taustalla olevien perintö-
tekijöiden löytyminen mahdollistaisi var-
haisen puuttumisen tautiprosessiin sekä
taloudellisten voimavarojen kohdenta-
misen juuri niihin potilaisiin, joilla on
munuaistaudille altistavat perintötekijät.
Tällöin taudin puhkeaminen voitaisiin
estää tai ainakin sen etenemistä voitaisiin
hidastaa.
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